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resumo 
 
 
As infeções do trato urinário, tecidos moles e intra-abdominal 
continuam a ser das principais causas de morbidade e mortalidade mundial. O 
uso excessivo e inadequado dos antimicrobianos tem levado ao aparecimento 
de diversas estirpes multirresistentes, sendo este um problema de saúde 
pública. A resistência aos antibióticos e a falta de novos compostos 
antimicrobianos leva a complicações terapêuticas. 
Neste estudo, avaliou-se a epidemiologia de estirpes produtoras de 
carbapenemases, bem como, a disseminação de AmpCs em isolados 
causadores de infeções do trato urinário e tecidos moles. Além disso, no 
sentido de avaliar novos compostos antimicrobianos realizou-se um estudo 
com o Ceftalozano/Tazobactam contra Enterobacteriaceae e Pseudomonas 
aeruginosa causadoras de infeções intra-abdominais.   
Os resultados obtidos mostraram a presença de blaKPC em 50 
Klebsiella pneumoniae, no total de 64 estirpes resistentes aos carbapenemos. 
Além disso, foram encontradas 155 estirpes Enterobacteriaceae produtoras de 
AmpC. Relativamente ao Ceftalozano/Tazobactam, este mostrou-se sensível 
contra quase todos os isolados (46/47).  
Ao longo deste estudo, verificou-se, também, que é essencial alarmar 
e sensibilizar as pessoas para estes problemas recorrendo essencialmente à 
educação. Como tal, realizou-se uma aula para 14 estudantes em risco de 
abandono escolar no Agrupamento de Escolas de Oliveirinha. Neste caso, os 
resultados foram positivos em mais de 70% dos casos. 
 Sendo assim, este estudo mostra a urgência de monotorização e 
controle epidemiológico em relação às estirpes multirresistentes. Da mesma 
forma, é direcionado para mitigar este problema com novas terapias e ideias 
para prevenir a resistência aos antibióticos baseados na educação.  
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abstract 
 
Urinary tract infections (UTIs), soft tissue infections (SSTIs) and intra-
abdominal (IAIs) infections continue to be the most important causes of 
morbidity and mortality around the world. The excessive and inappropriate use 
of antimicrobials has led to the emergence of several multi-resistant strains, 
which is a public health problem. Antibiotic resistance and the lack of new 
antimicrobial compounds lead to therapeutic complications.  
In this study, we evaluated the epidemiology of carbapenemases-
producing microorganisms, the dissemination of AmpCs in isolates causing 
UTIs and SSTIs. In order to evaluate new antimicrobial compounds, a study 
with ceftolozane/tazobactam against Enterobacteriaceae and Pseudomonas 
aeruginosa causing intra-abdominal infections was realized. 
The results showed the presence of blaKPC in 50 Klebsiella pneumoniae 
in a total of 64 carbapenem resistant strains. In addition, 155 AmpC-producing 
Enterobacteriaceae strains were found. Ceftolozane/tazobactam was effective 
against almost all isolates (46/47).  
Throughout this study, it has also been found that it is essential to raise 
awareness of these problems, through education. As such, a class was held for 
14 students at risk of dropping out at the “Agrupamento de Escolas de 
Oliveirinha”. In this case, the results were positive in more than 70%. 
In final, this study shows the urgency of monitoring and epidemiological 
control in relation to multi-resistant strains. Also, this work addresses new 
therapy to mitigate this problem and ideas to prevent antibiotic resistance 
based on education. 
 
  
Index  
General Introduction ………………………………………………………………………..1 
1. Hospital-acquired infections .................................................................................. 3 
1.1. Urinary tract infections ...................................................................................... 3 
1.2. Skin and soft tissues infections .......................................................................... 4 
1.3. Intra-abdominal infections ................................................................................. 5 
2. Microorganisms associated with infections ........................................................... 6 
3. Antimicrobials - β-lactam antimicrobials .............................................................. 7 
3.1. Cephalosporins .................................................................................................. 8 
3.2. Carbapenems ..................................................................................................... 9 
3.3. Ceftolozane/tazobactam..................................................................................... 9 
4. Antimicrobial resistance ........................................................................................ 9 
4.1. Mechanism of resistance (Gram-negative) – β-lactamases ............................. 11 
4.1.1. Classification of β-lactamases .................................................................... 12 
4.2. Extended-Spectrum β-lactamases (ESBLs) ..................................................... 13 
4.3. AmpC β-lactamases ......................................................................................... 14 
4.4. Mechanisms of resistance to carbapenems - Carbapenemases (KPC) ............ 15 
5. Organization and objectives of the dissertation ................................................... 16 
Material and Methods………………………………………………………………………...19 
1. Central Hospital characterization ........................................................................ 21 
2. Bacterial strains ................................................................................................... 21 
3. Identification and susceptibility testing ............................................................... 22 
3.1. VITEK®2 ......................................................................................................... 22 
3.1.1. Identification of bacterial strains ................................................................ 23 
3.1.2. Antimicrobial Susceptibility Testing (AST)............................................... 24 
3.1.3. Detection of extended-spectrum β-lactamases and AmpC β-lactamases 
producers microorganisms .................................................................................................... 24 
4. Phenotipic methods.............................................................................................. 25 
4.1. Detection of carbapenemases - RAPIDEC® CARBA NP ............................... 25 
  
4.2. Ceftalozane/tazobactam ................................................................................... 25 
5. Genotyping methods ............................................................................................ 26 
5.1. Polymerase Chain Reaction (PCR)...................................................................... 26 
Chapter I. Epidemiology of carbapenemases-producing bacteria in Centro Hospitalar do 
Baixo Vouga……………………………………………………………………………………..31 
Abstract…………………………………………………………………………………….33
1. Introduction ......................................................................................................... 34 
2. Results and discussion ......................................................................................... 35 
2.1. Characterization of bacterial strains ................................................................ 35 
2.2. Detection of blaKPC .......................................................................................... 36 
2.2.1. Klebsiella pneumoniae ................................................................................. 36 
2.2.1.1. Susceptible profile ................................................................................... 37 
2.2.2. Other Enterobacteriaceae ............................................................................ 38 
2.2.3. Pseudomonas aeruginosa ........................................................................... 38 
2.3. Strain typing: BOX analysis ............................................................................ 39 
2.4. Detection of plasmid IncFIA ........................................................................... 40 
3. Conclusion ........................................................................................................... 40 
Chapter II. Dissemination of AmpCs in Isolates Causing Urinary Tract Infections and Skin 
and Soft Tissues Infections in Centro Hospitalar do Baixo Vouga……………………………...41 
Abstract……………………………………………………………………………………..43
1.  Introduction ..... …………………………………………………………………44    
2. Results and discussion ......................................................................................... 35 
2.1. Bacterial strains characterization of urinary tract infections ........................... 45 
2.2. Bacterial strains characterization of skin and soft tissues infections............... 49 
3. Conclusion ........................................................................................................... 53 
Chapter III. Evaluate, in vitro, the activity of ceftolozane/ tazobactam against 
Enterobacteriaceae and Pseudomonas aeruginosa, which cause intra-abdominal infections.55 
Abstract…………………………………………………………………………………….57
1. Introduction ......................................................................................................... 57 
2. Results and Discussion ........................................................................................ 60 
  
2.1. Bacterial strains characterization ..................................................................... 60 
2.1.1. Extended-Spectrum β-lactamases producing Enterobacteriaceae .............. 62 
2.1.2. Multi-drug resistant Gram-negative ........................................................... 63 
2.2. Antimicrobial susceptibility testing ................................................................. 64 
2.2.1. Extended-Spectrum β-lactamases producing Enterobacteriaceae .............. 65 
2.2.2. Multi-drug resistant Gram-negative ........................................................... 66 
3. Conclusion ........................................................................................................... 67 
Chapter IV. Development of pedagogical materials for the antibiotic resistance awareness...69 
Abstract…………………………………………………………………………………….71
1. Introduction ......................................................................................................... 71 
2. Material and methods .......................................................................................... 74 
3. Results and Discussion ........................................................................................ 75 
4. Conclusion ……………………………………………………………………...76 
References…………………………………………………………………………………….77 
Annexes ……………………………………………………………………………………....85 
 
ANNEX I: Gram staining…………………………………………………………………….87 
ANNEX II: Poster ECCMID 2019 – “Surveillance of plasmid-mediated mcr-1 gene in human 
isolates, in Aveiro, Portugal”…………………………………………………………………….89 
ANNEX III: Poster SCICOM PT 2019 - Mobilidade de Ideias no Caminho da Inclusão…...91 
ANNEX IV: Poster SCICOM PT 2019 – “O (ir)resistível mundo dos antibióticos”………...95 
ANNEX V: Submitted abstract of ICID 2020 – Epidemiology of Carbapenemases-producing 
bacteria in Centro Hospitalar Baixo Vouga……………………………………………………...97 
 List of Figures 
 
General Introduction 
Figure 1 - Structures of the different β-lactam antibiotic classes…………………………………8 
Figure 2 - Mechanisms of resistance in Gram-negative microorganisms……………………….11 
Figure 3 - Hydrolysis of β-lactam antibiotics by β-lactamase enzymes…………………..……..12 
 
Methods and Material 
Figure 4 - Detail of the VITEK®2..……………………………………………………………....23 
Figure 5 - Plasmid structures of pBK30661, pBK30683 and the Tn4401/Tn1331 nested 
transposon in pBK15692..……………………………………………………………………….27 
 
Chapter I. Epidemiology of carbapenemases-producing bacteria in Centro Hospitalar 
Baixo Vouga 
Figure 6 - Isolates of suspected KPC-producer distributed by gender.………………………….35 
Figure 7 - Isolates of suspected KPC-producer considering if they were collected from inpatients 
and outpatients…………………………………………………………………………………...36 
Figure 8 - Presence (blaKPC +) or absence (blaKPC -) in K. pneumoniae isolates.………………..36 
Figure 9 - Isolates of K. pneumoniae grouped by typing, performed by BOX-PCR…………….39 
 
Chapter II. Dissemination of AmpCs in Isolates Causing Urinary Tract Infections and Skin 
and Soft Tissues Infections in Centro Hospitalar Baixo Vouga 
Figure 10 - Urinary tract infection distributed by gender.……………………………………….45 
Figure 11 - Distribution of the strains collected by age in urinary tract infections……………...46 
Figure 12 - Distribution of the UTIs isolates considering if they were collected from nosocomial 
and non-nosocomial ………..……………………………………………………………………47 
Figure 13 - Distribution of different strains, that caused or probably caused urinary tract 
infections, among all isolates tested positive for AmpC expression…………………………….47 
Figure 14 - Distribution of combined resistance mechanisms among AmpC positive strains…..48 
Figure 15 -  Distribuition of strains producer both AmpC and ESBL.…………………………..48 
Figure 16 - Skin and soft tissues infections distributed by gender………………………………49 
Figure 17 - Distribution of the strains collected by age in soft tissues infections……………….50 
Figure 18 - Distribution of the SSTIs isolates considering if they weew collected from 
nosocomial and non-nosocomial ………………………………………………………………..50 
 
  
 
Figure 19 - Distribution of different strains, that caused or probably caused SSTIs, among all 
isolates tested positive for AmpC expression........................……………………………………51 
Figure 20 - Distribution of combined resistance mechanisms among AmpC positive strains…..52 
Figure 21 - Distribution of strains producer both AmpC and ESBL…………………………….52 
 
 
Chapter III. Evaluate, in vitro, the activity of ceftolozane/ tazobactam against 
Enterobacteriaceae and Pseudomonas aeruginosa, which cause intra-abdominal infections 
Figure 22  - Chemical structure of ceftolozane…………………………………....……………..58 
Figure 23 - Chemical structure of tazobactam…………………………………...………………59 
Figure 24 - The different strains and our quantitative from IAIs………………………………..60 
Figure 25 - Distribution of the IAIs isolates considering if they were nosocomial and non-
nosocomial………………………………………………………………..……..……………….61
Figure 26 - Number of ESBL-producing microorganisms ………..…………………………….62 
Figure 27 - Strains of MDR microorganisms……………………………………………………63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
List of Tables 
 
Methods and Material 
Table 1 - Primer sequences for PCRs in this study………………………………………………28 
Table 2 - Programs for different PCRs…………………………………………………………..29 
 
Chapter I. Epidemiology of carbapenemases-producing bacteria in Centro Hospitalar 
Baixo Vouga 
Table 3 - Antibiotic resistant by K. pneumoniae isolates.……………………………………….37 
 
Chapter III. Evaluate, in vitro, the activity of ceftolozane/ tazobactam against 
Enterobacteriaceae and Pseudomonas aeruginosa, which cause intra-abdominal infections 
Table 4 - MIC50 values of susceptibility for Enterobacteriaceae and Pseudomonas 
aeruginosa………………………………………………………………………………………..64 
Table 5 - MIC50 values of susceptibility for Escherichia coli isolate with ESBL screen-positive 
phenotype and non-ESBL phenotype.…………………………………………………………...65 
Table 6 - MIC50 values of susceptibility for Klebsiella pneumoniae isolates with ESBL screen-
positive phenotype and non-ESBL phenotype.…………………………………………………..65 
Table 7 - MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates.…..66 
Table 8 - MIC50 values of susceptibility for MDR and non MDR Klebsiella pneumoniae 
isolates.…………………………………………………………………………………………..66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
List of Abbreviations 
AmpC - Ampicillin hydrolysing enzymes 
AST - Antimicrobial Susceptibility Testing 
blaAmpC - gene that confer resistant to  
β-lactamics 
blaCTX-M - gene that confer resistant to  
β-lactamics 
blaGES - gene that confer resistant to  
β-lactamics 
blaIMI - gene that confer resistant to  
β-lactamics 
blaIMP - gene that confer resistant to  
β-lactamics 
blaKPC - gene that confer resistant to  
β-lactamics 
blamcr-1 - gene that confer resistant to  
β-lactamics 
blaNDM - gene that confer resistant to  
β-lactamics 
blaNMC - gene that confer resistant to  
β-lactamics 
blaOXA - gene that confer resistant to  
β-lactamics 
blaSHV - gene that confer resistant to  
β-lactamics 
blaSME - gene that confer resistant to  
β-lactamics 
blaTEM - gene that confer resistant to  
β-lactamics 
blaVIM  - gene that confer resistant to  
β-lactamics 
CA-IAIs - Community-acquired intra-
abdominal infections 
CDC - Centre for Diseases Control and 
Prevention 
Ceft/Taz - Ceftolozane/Tazobactam 
CFU - colony-forming unit 
CHBV - Centro Hospitalar do Baixo Vouga 
cIAIs - Complicated intra-abdominal 
infections 
CLSI - Clinical and Laboratory Standards 
Institute guideline 
CPOs - Carabapenemase-producing 
organisms 
CRACKLE - Consortium on Resistance 
Against Carbapenems in Klebsiella and 
other Enterobacteriaceae  
CRE - Carbapenem-resistant 
Enterobacteriaceae 
cUTIs - Complicated urinary infections 
DNA – Deoxyribonucleic acid 
ECDC - European Centre for Diseases 
Prevention and Control 
EMA - European Medicines Agency 
ESBLs - Extended-spectrum β-
lactamasesESCPM group - Enterobacter 
cloacae, Enterobacter aerogenes, Serratia 
marcescens, Citrobacter freundii, 
Providencia spp., and Morganella morgani 
EU/EEA - European Union and European 
Economic Area 
 EUCAST - The European Committee on 
Antimicrobial Susceptibility Testing 
FDA - Food and Drug Administration 
HA-IAIs - Intra-abdominal infections 
associated with healthcare 
HAIs - Hospital-acquired infections 
HIP - Hospital Infante D. Pedro 
IAIs - Intra-abdominal infections 
ICU - Intensive care unit 
IncFIA - one of the plasmids responsible for 
carrying Tn4401d and blaKPC 
IncX-4 - one of the plasmids responsible for 
carrying blamcr-1 
MDR - Multidrug-resistant 
MICs - Minimal Inhibitory Concentrations 
MTS - MIC Test Strip 
PBPs - Penicillin-Binding Proteins 
PCR - Polymerase chain reaction 
PDR - Pan-drug-resistant 
RNA – Ribonucleic acid 
SMART - Study for Monitoring 
Antimicrobial Resistance Trends 
SSTIs - Skin and soft tissues infections 
Tn4401d - blaKPC located inside this 
transposon 
UTIs - Urinary tract infections 
XDR - Extensively drug-resistant 
  
General Introduction 
 
1 
 
 
 
 
 
 
 
 
General Introduction 
 
   
 
  
 
General Introduction 
3 
The present Master's thesis approaches one of the major public health problems around 
the globe, namely, in the area of microbiology. This problem is related to antibiotic resistance 
and outcomes that may arise in hospital infections caused by resistant microorganisms. Due to 
the excessive use of antibiotics, bacteria have developed several mechanisms of resistance, like 
the production of enzymes, which have the ability to be disseminated throughout the world. In 
addition, this work also addresses to new therapy to mitigate this problem and ideas to prevent 
antibiotic resistance based on education. 
 
1. Hospital-acquired infections 
 
Hospital-acquired infections (HAIs) are a major problem in public health. Complications 
during hospitalization may result in late recovery and increased costs. In the European Union and 
European Economic Area (EU/EEA) occurred more than 2-5 million new cases of each year, 
which lead to drastic impacts on morbidity and mortality (Chyderiotis et al. 2018). Normally, 
HAIs are associated with invasive medical devices, surgical procedures or environmental 
contamination (Peleg and Hooper 2012).  
The major lethal infections are related to lower respiratory tract and bloodstream, on the 
other end, the most common opportunistic infections are those of the urinary tract (Peleg and 
Hooper 2012; Smirnov and Egbert 2016; Ma and Hughes 2018). Also, skin and soft tissues 
infections (SSTIs) are common infections and intra-abdominal infections are the second most 
frequent source of bacteraemia (Dryden 2009; Maseda et al. 2014).  
 
1.1. Urinary tract infections  
 
 Urinary tract infections (UTIs) risk factors can be medical, behavioural and genetic. The 
risks factors of UTIs increase with age and structural or functional urinary tract impairments 
since they prevent the normal flow of urine. With the aging, the management of UTIs becomes 
more difficult, due to accumulating diseases, impairment of organ function, decreases 
physiologic reserve, increase of the frequency of reinfection and higher prevalence of generic 
drugs interaction. Premenopausal women have more UTIs than equivalent aged men. However, 
in the older population, the incidence in both genders increases and equalizes. Furthermore, 
medical conditions, such as, history of previous UTIs, diabetes, vaginitis and behaviour, like, 
sexual activity, use a diaphragm with spermicide and not voiding before/after intercourse are 
also a risk factor for a new UTI. In addition, genetic structural abnormalities, trauma from 
General Introduction 
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instrumentation, urinary stones or an enlarged prostate cause impairment to the flow of urine and 
these are also associated with UTIs (Ma and Hughes 2018). 
UTIs are classified based on clinical symptoms, laboratory data and microbiological 
findings. This type of infections is subdivided into two main categories, uncomplicated and 
complicated, varying in terms of severity and symptomatology (Grabe et al. 2015; Ma and 
Hughes 2018). 
Uncomplicated and acute UTIs include sporadic or recurrent episodes community 
acquired. Usually, they are acute cystitis (infection on the bladder, lower urinary tract) and acute 
pyelonephritis (infection of the kidney, upper urinary tract) in healthy individuals. These UTIs 
are seen mostly in healthy women, without structural and functional abnormalities in the urinary 
tract. A complicated UTI is an infection associated with structural or functional abnormalities of 
the genitourinary tract or the presence of an underlying disease, which increase the risk of a more 
serious outcome (Grabe et al. 2015).  
An infection in the upper urinary tract carries a risk of spread to the bloodstream which 
may eventually lead to sepsis (Smirnov and Egbert 2016).  
For optimal urinary tract infections treatment is necessary to know the pathophysiology, 
susceptibility of microorganisms that cause infection and find appropriate pharmacologic options 
(Ma and Hughes 2018).  
 
1.2. Skin and soft tissues infections 
 
Skin and soft tissues infections (SSTIs) are common, self-limiting and superficial 
infections to life-threatening diseases.  
These infections can be based on anatomical site, clinical severity of local, microbial 
cause (aetiology), and diagnosis (systemic signs) into uncomplicated or complicated. Soft tissues 
are underlying the skin and they include fat layers, fascia and muscle (Eron 2003; Dryden 2009). 
SSTIs are inflammatory microbial invasions of the epidermis, dermis and subcutaneous 
tissues (Dryden 2010).  
Successful management of SSTIs involves prompt recognition, adequate antibiotic 
therapy and surgical intervention, if required. For the treatment of these infections are indicated 
some β-lactams. In polymicrobial infections, the therapy indicated is β-lactam/ β-lactamase 
inhibitor combinations (Dryden 2010). In addition, tigecycline (minocycline derivative with a 
broader spectrum of activity) is approved for the treatment of complicated skin and soft-tissue 
infections (Peleg and Hooper 2012). 
General Introduction 
5 
1.3. Intra-abdominal infections 
 
Intra-abdominal infections (IAIs) are the second frequent most source of bacteraemia 
(Maseda et al. 2014). 
IAIs are subdivided into uncomplicated (e.g. acute diverticulitis and certain forms of 
acute appendicitis) and complicated infections (Sartelli et al. 2013). These terms are used to 
differentiate clinical situations and categorize the severity of infections for treatment 
recommendations (Maseda et al. 2014). Complicated intra-abdominal infections (cIAIs) include 
a very large variety of infectious processes and are an important cause of infection. There are 
different sources of infection, such as biliary obstruction, gallbladder, gastroduodenal, 
appendiceal or small and large bowel perforations. When patients are diagnosed with peritonitis 
or with sepsis syndromes, mortality rates are particularly high (Eckmann and Solomkin 2015). 
Moreover, intra-abdominal infections can be classified into two groups: community-
acquired intra-abdominal infections (CA-IAIs) and intra-abdominal infections associated with 
healthcare (HA-IAIs). CA-IAIs are directly acquired from the community; while HA-IAIs 
develop in patients hospitalized or residents in health facilities for long period. HA-IAIs are 
usually associated with higher rates of mortality. This can be explained since these patients have 
a deficient immune system, leading to major probability of infection by microorganisms and 
involvement of resistant pathogens is higher (Sartelli et al. 2013; Maseda et al. 2014). 
Principal risk factors in IAIs are associated with age (greater than 70 years), 
immunosuppression, chronic dialysis, a large number of comorbidities, admission in a 
healthcare, internment of the patients, recent surgical procedure, recent urinary catheterization, 
use recent of antimicrobial agents (such as β-lactams and quinolones) and recent story of 
colonization of MDR (Labricciosa et al. 2018). 
Control of intra-abdominal infections depends of the patient's characteristics 
(comorbidity and previous antibiotic treatment), local resistance data, the context (intensive care 
unit (ICU), hospital ward) and the origin of the infection (acquired in the community, associated 
with healthcare or nosocomial) (Maseda et al. 2014). Surgery is the most important therapeutic 
recourse for controlling intra-abdominal infections. When surgical intervention is required, 
usually 24-hour perioperative prophylaxis is performed. In contrast, patients with uncomplicated 
IAIs may be treated non-operatively (Sartelli et al. 2013).  
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2. Microorganisms associated with infections 
 
In 2010, the U.S. National Healthcare Safety Network indicated that Gram-negative 
bacteria are responsible for more than 30% of HAIs and the Enterobacteriaceae family being the 
most commonly identified group overall (Peleg and Hooper 2012). Enterobacteriaceae are large 
and diverse family of Gram-negative rods and microorganisms are facultative anaerobic. This 
family has members free-living and part of the microbiome (lower gastrointestinal tract), actually 
some of these are adapted strictly to living in humans. This family may cause diseases when they 
gain access to normally sterile body sites through the help of surface structures, as pili (Smirnov 
and Egbert 2016). 
For example, Gram-negative microorganisms, mainly Enterobacteriaceae, are the most 
common cause of UTIs and IAIs (Maseda et al. 2014; Ma and Hughes 2018).  
The most associated microorganism with SSTIs is Staphylococcus aureus, a Gram-
positive bacterium that can produce a variety of toxins and may potentiate their virulence, 
followed by P. aeruginosa, E. coli and Enterococcus spp. (Dryden 2009). 
In addition, the Klebsiella pneumoniae is the most common microorganisms resistant to 
carbapenems, since is the most prevalent species producing and carrying a blaKPC,  
 
As mentioned above, P. aeruginosa is one of the most prevalent microorganism that 
causes UTIs and is one of the major nosocomial pathogens worldwide (Sader et al. 2014). P. 
aeruginosa is an aerobic, motile, Gram-negative rod, slimmer and more pale staining than 
members of the Enterobacteriaceae. The total number of infections caused by P. aeruginosa is 
higher than the other species of Pseudomonas (Smirnov and Egbert 2016). This microorganism 
represents around 6% of all Gram-negative bacilli isolated from shock septic in ICU patients; 
and when are established infections are virulent and difficult to treat (Maseda et al. 2014; 
Smirnov and Egbert 2016).  
Usually, affected patients are almost always debilitated or with immune defences 
compromised. For initiate infection, the P. aeruginosa needs to a break in defences of first-line 
(like a wound) (Smirnov and Egbert 2016). In patients with severe P. aeruginosa infection, the 
prompt initiation of adequate antimicrobial therapy is extremely important. The delay in the 
initiation of appropriate antimicrobial therapy is associated with increased morbidity and 
mortality (Sader et al. 2014). 
An increase of infections caused by P. aeruginosa and Enterobacteriaceae lead to an 
increase of morbidity and mortality (Mohamed et al. 2018). 
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3. Antimicrobials - β-lactam antimicrobials 
 
In the first half of 20th-century, the discovery and synthetic production of antibiotics, and 
their subsequent introduction in medicine revolutionized this area, permitting the treatment of 
once incurable infections. Nowadays, antibiotics are necessary for overall practice of medicine, 
such as, surgeries, treatment of cancer, organ transplantation and for immunocompromised 
patients, among others and reduction of the morbidity and mortality (Van Hoek et al. 2011; Khan 
et al. 2018). 
Nowadays, a number of different antimicrobial agents known is large and can be 
classified based on their mechanisms of action. Antibiotics can inhibit protein synthesis 
(aminoglycosides, chloramphenicol, macrolides, streptothricin, and tetracycline) or interact with 
the synthesis of DNA and RNA (quinolones and rifampin). Also, can inhibit or damage synthesis 
of bacteria cell wall (β-lactams and glycopeptides) or modify energy metabolism of a microbial 
cell (sulphonamides and trimethoprim) (Van Hoek et al. 2011). 
Nonetheless, the β-lactams are the class of antibiotics that are more frequently used in the 
treatment of infectious diseases (Moya et al. 2009). 
 
One of the first antibiotics discovered was a β-lactam, the penicillin, in 1924. 
Over the last years, many new β-lactam antibiotics were developed maintaining a β-lactam ring 
in their molecular structure (Van Hoek et al. 2011). 
The success of β-lactam antibiotics against most of the Gram-negative pathogens depends 
essentially on the (i) concentration of antibiotic that reaches the periplasmic space; (ii) resistance 
to the chromosome-encoded AmpC β-lactamases and extended-spectrum β-lactamases (ESBLs) 
and (iii) the affinity against main targets of the β-lactam antibiotics, such as penicillin-binding 
proteins (PBPs) (Moyá et al. 2010; Thomson 2010). The concentration reached in the 
periplasmic space depends on the balance between diffusion through the outer membrane and 
expulsion by the efflux pumps. The resistance of AmpC is dependent on whether it does or does 
not prevent the induction of β-lactamases (Moyá et al. 2010). β-lactams act similarly by binding 
and inactivating the PBPs, which are proteins involved in biosynthesis and remodelling of 
peptidoglycan structure in the bacterial cell wall. Failure in PBPs results in inhibition of cell wall 
synthesis and consequent cell death (Llarrull et al. 2010; Eckmann and Solomkin 2015). 
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This family includes penicillins and derivates, cephalosporins, carbapenems, 
monobactams and β-lactams inhibitors (Figure 1) (Van Hoek et al. 2011). 
 
 
3.1. Cephalosporins 
 
Despite the cephalosporins are thought to be a new derivate of penicillin, in fact, they are 
naturally occurring substances. According to a different spectrum of activity and timing of the 
agent’s introduction, can be differentiated cephalosporins into four groups (first, second, third 
and fourth generation) (Van Hoek et al. 2011).  
In general, first-generation of cephalosporins have good activity against Gram-positive 
and relatively modest coverage for Gram-negative microorganisms; second-generation of 
cephalosporins have increased Gram-negative and somewhat less Gram-positive activity; third 
generation of cephalosporins have improved Gram-negative activity and variable Gram-positive 
activity; fourth generation of cephalosporins have broad-spectrum activity against both Gram-
negatives and Gram-positives microorganisms (Van Hoek et al. 2011). 
Also, there are some cephalosporins that show antipseudomonal activity, such as 
ceftazidime and cefotaxime, since they bind preferentially to PBP3 (present in P. aeruginosa), 
leading to formation of filaments (Moyá et al. 2010).  
 
 
 
 
Figure 1 - Structures of the different β-lactam antibiotic classes (Van Hoek et al. 2011) 
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3.2. Carbapenems 
 
Carbapenems are widely used because they are a sub-class of β-lactam antibiotics with a 
wide range of antibacterial activity (Bina et al. 2015). In addition, carbapenems were 
recommended for the treatment of infections caused by MDR microorganisms (Mohamed et al. 
2018). Carbapenems, like imipenem, bind to PBP2 (present in P. aeruginosa), which leads to the 
conversion of rod-shaped cells into spherical cells; and peptidoglycan cross-linking is 
compromised, preventing the cell wall synthesis, leading to cell lysis (Moyá et al. 2010; Sebaaly 
et al. 2018). 
 
Furthermore, excessive use of broad-spectrum antibiotics in hospitalized patients has lead 
to development of MDR strains, which increase mortality, morbidity and rates of antibiotic 
resistance (Santos et al. 2011; Magalhães et al. 2017; Khan et al. 2018).  
 
3.3. Ceftolozane/tazobactam 
 
Ceftolozane/tazobactam (Ceft/Taz) is a new antibiotic resulting from the combination of 
a novel third generation cephalosporin, similar to ceftazidime, with tazobactam, a β-lactamase 
inhibitor. This antimicrobial has activity against extended-spectrum β-lactamases (ESBL)-
producing Enterobacteriaceae. In addition, Ceft/Taz has stability when in the presence of AmpC 
β-lactamases and good pseudomonal activity, which makes it stable against the most common 
resistance mechanisms of P. aeruginosa resistant. Recently, the U.S. Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) have approved Ceft/Taz for 
the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary 
infections (cUTI). Therefore, Ceft/Taz is an alternative to carbapenems for the treatment of 
infections caused by ESBLs microorganisms (Maseda et al. 2014; Giacobbe et al. 2018; 
Mohamed et al. 2018; Sheu et al. 2018).  
 
4. Antimicrobial resistance 
 
The World Health Organization and the United Nations considered antibiotic resistance 
as one of the most important public health of the 21st-century. According to the Centre for 
Disease Control and Prevention, more than 700,000 people die around the world due to resistant 
infections (Khan et al. 2018).  
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In preceding decade, it was seen an increase in antimicrobial resistance in nosocomial 
and community pathogens. The microorganisms have several mechanisms that allow them to 
adapt to stress, such as genetic mutations (acquisition or sharing of genetic material) and the 
modulation of genetic expression (Khan et al. 2018). This adaptation is conferred by genes, 
which are located on transferable plasmids and can be transferred between bacteria, between 
regions and countries and spreading throughout the world (Bina et al. 2015). This genetic 
plasticity may lead to resistance to several antimicrobials used in clinical practice. This 
phenomenon is not recent and is widespread in nature; mutations and/or acquisition of genes 
make microorganisms “intrinsically” resistant. Also, exist pathogens with “acquired resistance” 
and that is the most concerning issue in clinical settings (Khan et al. 2018).  
The medical literature characterizes different standards of resistance found in 
antimicrobial resistance in health care.  A group of international experts (European Centre for 
Diseases Prevention and Control, ECDC and Centre for Diseases Control and Prevention, CDC) 
created a standardized worldwide terminology, which describes acquired resistance profiles of 
all bacteria responsible for healthcare-associated infection and susceptible to multidrug 
resistance. They established the terms such as multidrug-resistant (MDR), extensively drug-
resistant (XDR) and pan-drug-resistant (PDR). MDR was defined as resistant to at least three or 
more antimicrobial agents. In XDR bacterial isolates remain susceptible to only one or two 
categories. PDR was defined as non-susceptibility to all agents in all antimicrobial categories 
(Magiorakos et al. 2011).  
The evolution antibiotic resistance mechanisms and the lack of the antimicrobial agents 
lead to a key problem for clinicians (Bina et al. 2015). 
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4.1. Mechanism of resistance (Gram-negative) – β-lactamases 
 
Infections caused by Gram-negative bacteria, for example, Enterobacteriaceae and P. 
aeruginosa, are a major cause of concern. These organisms are highly efficient in the acquisition 
of antibiotic resistance mechanisms, such as loss of porins (family of proteins on the outer 
membrane of Gram-negative bacteria that allow diffusion of the substrate, such as, antibiotics), 
increased expression of the transmembrane efflux pump, the presence of antibiotic-modifying 
enzymes, target site mutations, ribosomal mutations or modifications, metabolic bypass 
mechanisms and mutation in the lipopolysaccharide (Peleg and Hooper 2012). Gram-negative 
bacteria combine porin selection (or deletion) to minimize β-lactams access to the PBPs, active 
efflux to facilitate β-lactams removal (Llarrull et al. 2010) (Figure 2).  
 
The generalized commercial use of antibiotics, the diversity, spread, distribution, host 
diversity and prevalence of β-lactamases activity has increased exponentially. Gram-negative 
bacteria produce β-lactamases, enzymes which give them resistance to the action of β-lactam 
antibiotics, since destroy them (Harris 2015) (Figure 3).  
 
Figure 2 - Mechanisms of resistance in Gram-negative microorganisms (Peleg and Hooper 2012) 
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The emergence of new β-lactamases confers resistance to the most β-lactam antibiotics, 
for example, penicillins, carbapenems and cephalosporins (Bina et al. 2015).  
 
β-lactamases can be subdivided into narrow-, moderate-, broad-, and extended-spectrum 
β-lactamases (ESBLs), based on their activity to hydrolyse a small or considerable number of β-
lactams. The broad-spectrum β-lactamases confer resistance to penicillins and cephalosporins; 
however, inhibitors of β-lactamases, such as clavulanic acid and tazobactam, do not inhibit them. 
In other hand, the ESBLs are capable to provide resistance to the penicillins, cephalosporins 
(first-, second-, and third-generation) and aztreonam, but the susceptibility to the carbapenems is 
maintained and they are inhibited by β-lactamases inhibitors (Van Hoek et al. 2011).  
 
4.1.1. Classification of β-lactamases 
 
Over the years, several classification systems for β-lactamases were accepted among 
researchers. However, only two classification schemes predominated: the classes A to D 
proposed by Ambler, based on homology of amino acid sequences of β-lactamases type and the 
Bush-Jacoby–Medeiros functional classification scheme (into four groups (1 to 4) and several 
subgroups (a to f)). According to Ambler, the division of β-lactamases based on the molecular 
structure: types A, C, and D with a serine residue at the active site and class B metalloenzymes 
with a Zn2+ cofactor. On other hand, the classification by Bush-Jacoby-Medeiros defines the β-
lactamases based on their substrate and inhibitor profiles (Harris 2015).  
The first proposal for β-lactamases classification based on the molecular structure was 
made by Ambler, in 1980, when only four amino acid sequences were known (Bush et al. 1995). 
In this case, different properties were used to differentiate and classify the β-lactamases, such as: 
isoelectric point, molecular mass, relative activity towards different β-lactams (‘substrate 
Figure 3 - Hydrolysis of β-lactam antibiotics by β-lactamases enzymes (Harris 2015) 
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profile’), interaction with inhibitors and inactivators, nature of the active site, amino acid 
sequence, and three-dimensional structure (Brito and Lopes 2016).  
The Bush–Jacoby–Medeiros functional classification scheme classifies the β-lactamases 
according to their substrate and inhibitor profile: (i) cephalosporinases of group 1, are not well 
inhibited by clavulanic acid; (ii) group 2 penicillinase, cephalosporinases and broad spectrum β-
lactamases are generally inhibited by β-lactams directed to the active site; and (iii) the metallo-β-
lactamases of group 3, hydrolyse penicillins, cephalosporins and carbapenems, and are also 
poorly inhibited by almost all molecules containing β-lactams (Bush et al. 1995; Harris 2015).  
 
Increased resistance to β-lactams is reflected in an increase of infections caused by 
bacteria that expresses ESBLs. In addition, there are bacterial species that possess 
chromosomally encoded broad-spectrum cephalosporinases (AmpC β-lactamases) (Harris 2015). 
From the clinical point of view, ESBLs, AmpCs and carbapenemases are the most relevant β-
lactamases (Khan et al. 2018). 
 
4.2. Extended-Spectrum β-lactamases (ESBLs) 
 
The proliferation of β-lactamases, namely, extended-spectrum β-lactamases (ESBLs) is 
worrisome (Sader et al. 2014). These enzymes are a big problem because they are capable to 
provide resistance to penicillins and cephalosporins (first-, second-, and third generation). In 
addition, these enzymes they have been increasingly described in AmpC producers. The Study 
for Monitoring Antimicrobial Resistance Trends (SMART) show that 8.5 to 11.2 % of all 
enterobacterial isolates around the world are ESBL-producing isolates (Van Hoek et al. 2011; 
Maseda et al. 2014). 
Exist some risks factors for ESBLs, such as, the excessive use of third-generation 
cephalosporins, aminoglycosides and quinolones, previous hospitalization, advanced age, 
diabetes and use of catheters in ICU patients (Maseda et al. 2014). 
There are several and different types of ESBLs, namely CTX-M, TEM, SHV and OXA, 
encoded by plasmids. CTX-M enzymes are one of the most notable ESBLs since they are 
disseminated on plasmids in Enterobacteriaceae and subsequently they were rapidly 
disseminated worldwide (Van Hoek et al. 2011; Weinstein and Logan 2012; Sader et al. 2014; 
Khan et al. 2018). When microorganisms are hospital-acquired, SHV-type and TEM-type ESBLs 
are predominant. Nonetheless, the epidemiology of ESBLs is changing, since amino acid 
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alterations in enzymes give place to extended-spectrum enzymes with broader substrate 
specificities (Jacoby 2009; Peleg and Hooper 2012).  
 
4.3. AmpC β-lactamases 
 
AmpC (ampicillin hydrolysing enzymes) β-lactamases are clinically important 
cephalosporinases. Nomenclature for AmpCs refers to a family of related enzymes, not to the 
same protein produced in a variety of microorganisms (Bush et al. 1995; Iredell et al. 2016).  
AmpC β-lactamase of E. coli was the first bacterial enzyme reported to destroy penicillin 
named as such in 1940. In Ambler structural classification of β-lactamases, belong to class C; 
while in the functional classification of Bush–Jacoby–Medeiros, they were assigned to group 1 
(Jacoby 2009; Harris 2015). Although these are less common than ESBLs, they have been found 
in several areas of the world. AmpCs are essentiality isolated from patients after several days of 
hospitalization, from long-term care facilities, rehabilitation centres and outpatient clinics 
(Jacoby 2009; Dallenne et al. 2010).  
AmpC enzymes can be both chromosomal and plasmid encoded (Maseda et al. 2014).   
These enzymes are intrinsic in certain species, such as, Enterobacter cloacae, 
Enterobacter aerogenes, Serratia marcescens, Citrobacter freundii, Providencia spp., and 
Morganella morganii – the ESCPM group. Also, non-fermenters bacteria like P. aeruginosa has 
AmpC enzymes with homology to those seen in Enterobacteriaceae (Harris 2015). 
Chromosomally-encoded expression of AmpC β-lactamases is induced by exposure to β-lactams 
in many Gram-negative bacteria (Worthington and Melander 2013).  
Under β-lactams exposure, AmpCs production is controlled by transcription factors 
(metabolites of peptidoglycan) and regulators levels. Regulators, like AmpR, respond to changes 
in cell-wall cycling pathways, leading to strong increases in AmpC levels and expression – 
inducible expression, present in E. coli. In lack of an inducer (absence of antibiotics), AmpR 
regulator element inhibits blaAmpC expression as it interacts with peptidoglycan precursors, which 
repress AmpC expression. When the β-lactams exposition stops, the levels of AmpC usually 
return to baseline and do not alter the effect of β-lactams. In other words, there are various 
species have AmpC enzymes with differences in expression levels and clinical significance 
(Harris 2015; Khan et al. 2018).  
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Acquisition of blaAmpC by plasmids is known since 1989, when they were detected in 
enterobacteria, which were not expected to produce plasmidic blaAmpC, like E. coli and K. 
pneumoniae. Plasmidic blaAmpC mediate resistance to most penicillins (e.g. amoxicillin), first-
generation cephalosporins to third generation cephalosporins and β-lactam/ β-lactamase inhibitor 
combinations. Furthermore, plasmid mediation of blaAmpC lead to its dissemination for others 
organisms within a hospital or geographic region (Alvarez et al. 2004; Jacoby 2009; Harris 
2015). 
 
4.4. Mechanisms of resistance to carbapenems - Carbapenemases (KPC) 
 
Resistance to carbapenems has become common, representing around 20% of multidrug 
resistance (Maseda et al. 2014). Resistance to carbapenems can be conferred by a decrease in 
bacterial outer membrane permeability, through alterations or loss of porins. Deletions or 
mutations of porin gene difficult this diffusion and is the most common resistance mechanisms 
in Gram-negative bacteria. In addition, production of cephalosporinases combined with 
mutations also lead to decrease permeability of the bacterial cell wall. Increased ESBLs and 
AmpCs production and the expression carbapenemases are also mechanisms of resistance to 
carbapenems (Weinstein and Logan 2012; Bina et al. 2015; Bonomo et al. 2018).  
 
Carbapenemases are enzymes that hydrolyse carbapenems and are able to break other β-
lactam antibiotics, including penicillins, cephalosporins and monobactams (Weinstein and Logan 
2012). Production of carbapenemases is the most important mechanism of enzymatic 
carbapenems resistance in Enterobacteriaceae, since in this family, carbapenemases have high 
capacity of dissemination and these microorganisms are prone to colonize patients in healthcare 
settings. The genes of carbapenemases are located in mobile genetic elements, which increases 
their spread (Bonomo et al. 2018).  
The molecular structure classification of carbapenemase based in Ambler belong to class 
A, B and D. These classes are distinguished by the active site of the hydrolytic mechanism. Class 
A and D of carbapenemases require serine at their site (known serine carbapenemases), while 
class B are zinc-dependent, the metallo-β-lactamases. Class A carbapenemases include K. 
pneumoniae carbapenemase (KPC), IMI (imipenem-hydrolyzing enzyme), SME (Serratia 
marcescens enzyme), GES and NMC (not-metallo-enzyme carbapenemase). Most of these 
enzymes are chromosomally encoded, however blaKPC is often carried on a mobile plasmid or 
transposon. This allows KPC to be the most common enzyme disseminated among 
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Enterobacteriaceae. On other hand, class D can be able to hydrolyse oxacillin (OXA 
carbapenemase); have been found more commonly in P. aeruginosa, Acinetobacter species and 
in Enterobacteriaceae. In contrast, class B include the plasmid-based Verona integron-encoded 
MBL (VIM) and IMP; after that New Delhi MBL (NDM) gained much attention because it has 
spread quickly globally into Enterobacteriaceae species (Weinstein and Logan 2012; Khan et al. 
2018).  
KPC enzyme is encoded by the blaKPC, located inside a transposon Tn4401 which allows 
it to spread among different species. This transposon is able to enter into various Gram-negative 
bacterial plasmids. Although K. pneumoniae is the most prevalent species producing and 
carrying a blaKPC, this gene has also been identified in another Gram-negative bacillus (Bina et 
al. 2015). The problem of the production of carbapenemases increases when it’s found in 
Enterobacteriaceae. Since this group of bacteria has a high capacity to disseminate and colonize 
patients in healthcare settings, which leads to a high concern in the prevention and transmission 
of these microorganisms (Bonomo et al. 2018). 
The prevalence of carbapenemases remains low nonetheless one can not forget that their 
spectrum of activity encompasses all known β-lactams (from penicillins to carbapenems). In this 
way, it’s necessary to find new alternatives, such as turn once again to combinations of β-lactam 
antibiotics and β-lactamase inhibitors (Maseda et al. 2014). 
 
 
5. Organization and objectives of the dissertation 
 
The main objectives of this dissertation are: to study antimicrobial resistance, as well as 
the problems that arise and new alternatives to this problem. 
This dissertation is organized into general introduction and four chapters, namely:   
1 - In the first chapter of this work, we intend to evaluate the epidemiology of 
carbapenemases produced by bacteria in the Centro Hospitalar do Baixo Vouga.  
2- In the second chapter of this work, the dissemination of AmpC β-lactamases in isolates 
causing urinary tract infections and soft tissues infectious in the Centro Hospitalar do Baixo 
Vouga was evaluated.  
3 - The third chapter of this dissertation intended to evaluate, in vitro, ceftalozane/ 
tazobactam strips activity against strains of Enterobacteriaceae and P. aeruginosa isolated from 
intra-abdominal infections. 
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4 - The fourth chapter approaches the global theme present in this dissertation: resistance 
to antibiotics. In this chapter, pedagogic material was developed and the message passed to the 
general public. 
These chapters reflect the experimental work done and are independent of each other. 
Each of these chapters is composed of the following sections: introduction, results and 
discussion and conclusion. 
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1. Central Hospital characterization 
 
The present study was performed in Microbiology laboratory of the Clinical Pathology 
department, in the “Centro Hospitalar do Baixo Vouga, E.P.E. – Hospital Infante D. Pedro 
(HIP)”. HIP is one of the three units that compose the “Centro Hospitalar do Baixo Vouga 
(CHBV)” and includes several wards, include pathologic anatomical, anesthesiology, cardiology, 
general surgery, general medicine, dermatology, endocrinology, stomatology, gastroenterology, 
gynecology/obstetrics and infectiology, among others. 
Nowadays, the Clinical Pathology department, include all the main functional areas of 
clinical-laboratory research and to perform diagnostic tests. This department is composed of the 
following sectors: general biochemistry, immunology/ autoimmunity and allergology, 
haematology, laboratory coagulation and microbiology. The mission is to ensure the laboratory 
tests necessary for laboratory diagnosis lead to increase the level of health protection, that 
operates 24 hours a day. This department supports hospitalization, external consultation, 
operating room, outpatient surgery, day hospital, emergency service and provide laboratory 
support to other health institutions, namely in the region of Aveiro. 
Microbiology laboratory realizes tests that contribute to diagnosis, treatment, monitoring 
and prevention of diseases. Clinical diagnosis makes it possible to detect which microorganism 
causes an infection and which resistance and/or susceptibility to antimicrobials, being essential 
for the success of patient treatment.  
 
2. Bacterial strains 
 
In the present study, microorganisms were isolated, from both inpatients and outpatients 
and according to the different objectives of each chapter. The samples were collected between in 
2017 and 2018. 
In chapter I, carbapenemases-producing bacteria were isolated, from January 2017 to 
March 2019 with different clinical histories. In this case, it was evaluated the main mechanisms 
of resistance to carbapenems. 
In chapter II, Gram-negative strains producing AmpC β-lactamases, causing urinary tract 
infections and soft tissues infections were isolated from September to December 2018.  
In chapter III, Gram-negative strains from patients with complicated intra-abdominal 
infections were isolated from September to November 2018. These strains should be extended-
spectrum β-lactamases (ESBLs) and/or AmpC β-lactamases producers. 
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The workflow for each sample followed the laboratory procedures for each biological 
product. Briefly, samples were inoculated in the appropriate culture medium, and incubated for 
different hours, depending by local of harvest, at 35 ℃. It should be noted that in order to obtain 
reliable results, it is necessary that the biological products be harvested correctly. Non-
significant, dubious and significant bacteriuria is considered when the count is <103 CFU/ ml, 
10-100 CFU/ ml and ≥105 CFU/ ml, respectively. 
The strains of interest were placed in hypertonic cryopreservative solution and stored at -
20 ℃, in eppendorf, until further use.  
Considering the provenance of the patients, the microorganisms were classified as 
nosocomial and non-nosocomial. If they were collected from patients in the emergency room or 
external consultation, the microorganisms were considered non-nosocomial. On the other hand, 
if patients were in the hospital for 72h or more, the microorganism was considered nosocomial. 
 
3. Identification and susceptibility testing  
 
Several phenotypic tests are performed in order to achieve a presumptive identification of 
the bacteria. Identification of the bacterial species and antibiotic susceptibility profile was 
performed by an automatic detection system, VITEK®2. 
 
3.1. VITEK®2 
 
VITEK®2 is an automated system that allows the identification of the bacterial species 
and antibiotic susceptibility pattern of the microorganism in a 24-hour period,  
through the inoculation and incubation of cards of identification, created for this purpose. 
VITEK®2 is configured according to the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) and VITEK®2AES software (Advanced Expert System) (BioMérieux, Marcy 
L'Étoile, France). The system is based on an optic system combining a multichannel fluorometer 
and photometer that registers alterations in fluorescence, turbidity and colour.  
Identification cards were used for Gram-negative microorganisms (GNI). After this 
identification, the respective antimicrobial susceptibility cards are selected. In this work, AST-
N373 and AST-N355 cards were used for susceptibility to antimicrobials in Gram-negative 
microorganisms. 
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Figure 4 - Detail of the VITEK®2.  
The VITEK®2  it’s composed by [1] Computer hardware support; [2] Inoculation of the 
microbial suspension in the tubes and positioning of the identification letters in the cassette; [3] 
Identification of the card, by reading bar code; [4] Identification of the sample, which will be 
associated with a particular letter identified in the previous point; [5] The suspension is 
inoculated into the wells of the respective identification letter; [6] The cassette is transported to 
the player; [7] The results are automatically printed when the chart reading is complete and [8] 
After identification of the microorganism present in the bacterial suspension, the charts are 
removed from the equipment. 
 
3.1.1. Identification of bacterial strains (ID) 
 
The identification is made from a fresh and pure culture, from where a suspension of 0.55 
to 0.65 McFarland of bacteria is achieved and inoculated through a vacuum system into the 
chosen cards. The cards are incubated at 35.5 ± 1 ° C and read every 15 minutes. 
For identification, the results of a set of 64 tests are taken into account. To identify the 
microorganisms, there are four distinct cards available: 1) Gram-negative bacilli, fermenters or 
non-fermenters; 2) Gram-positive cocci and ex-non-sporulated bacilli; 3) yeasts; 4) cocci formed 
by Gram-positive spores. Each card has several wells containing biochemicals (evaluating the 
metabolic activity of the organism: acidification, alkalization, enzymatic hydrolysis or growth in 
the presence of inhibitors) and a well containing a growth control agent. The results are 
compared with a database of well-characterized strains, and an identification is obtained with a 
certain degree of similarity of the metabolic test. 
The identification usually requires from 18h to 24h of incubation in the VITEK®2 
Reader/Incubator. 
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3.1.2. Antimicrobial Susceptibility Testing (AST)  
 
The antimicrobial susceptibility testing (AST) is indicated for all microorganisms that 
contribute to an infectious process and justify antimicrobial therapy. This test is based on the 
determination of minimal inhibitory concentrations (MICs) using different concentrations of 
antibiotics and is therefore determined from the lowest concentration at which inhibition of 
bacterial growth occurs. The AST was performed with the aid of VITEK®2 equipment. 
The inoculum performed for the identification of the microorganism is sufficient to the 
antibiogram, and the suspension should have a density equivalent to a standard between 0.5 and 
0.65 on the MacFarland scale for Gram-negative and Gram-positive bacteria. In all cards there is 
a control well, which contains only microbiological culture medium. 
Each AST card has 64 microwells with selected antibiotics and in varying concentrations. 
The device monitors growth in each of the cards wells over a defined period of time (up to 18 
hours for bacteria). The system determines which well shows growth of the microorganism 
based on the decrease in light intensity that is measured by the optical reader. At the end of the 
incubation cycle, an interpretive result (Sensitive, Intermediate or Resistant) relative to the 
antimicrobial agent will be marked together with an MIC, according to interpretations defined by 
the EUCAST guidelines. 
 
3.1.3. Detection of extended-spectrum β-lactamases and AmpC β-lactamases 
producers microorganisms 
 
Escherichia coli and Klebsiella pneumoniae species were screened for the presence of 
ESBLs. ESBL producers are identified by the automated system (VITEK®2) and were confirmed 
using phenotypic tests (E-test). 
The suspected AmpC producers were selected based on the resistance to amoxicillin/ 
clavulanic acid. 
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4. Phenotipic methods 
 
4.1. Detection of carbapenemases - RAPIDEC
®
 CARBA NP 
 
RAPIDEC® CARBA NP (BioMèrieux, France) is a rapid test that provides reliable 
results in less than 2 hours for carbapenemases producing bacteria. This has a high clinical value 
since it confirms the presence of bacteria producing carbapenemases. This allows to confirm the 
diagnosis and to help guide the treatment of the patient. 
The RAPIDEC® CARBA NP test detects the hydrolysis of carbapenems by 
carbapenemase-producing bacteria: Enterobacteriaceae, Pseudomonas aeruginosa and 
Acinetobacter baumannii. The hydrolysis acidifies the medium, which gives rise to the colour 
change of the pH indicator - specifically indicating the presence of resistance to transmissible 
carbapenems. It detects (without distinction) the 3 types of carbapenemases produced: KPC, 
metallo-β-lactamases (NDM-1, VIM, IMP) and carbapenemases of type OXA (Poirel and 
Nordmann 2015). 
 
4.2. Ceftalozane/tazobactam 
 
Minimal inhibitory concentrations (MICs) for Ceftolozane/Tazobactam were determined 
using a quantitative method – MIC Test Strip (MTS), with a predefined gradient of concentration 
that ranges between 0.016/4 - 256/4 μg/ mL, according to Liofilchem (Liofilchem, Italy) 
standards. MTS consists of special paper impregnated with a pre-defined concentration gradient 
of an antimicrobial agent, which is used to determine MIC in µg/ mL of antimicrobial agents 
against bacteria as tested on agar media using standard incubation temperature (35 ± 2 °C) and 
time (16–20 h).  
The stored strains were plated with inoculation loop in PVX medium and incubated at 37 
℃. A fresh and pure colony was taken, with a sterile swab, into the saline solution to achieve a 
suspension of 0,50 McFarland (for verification this density a densitometer was used). The 
suspension was than spread into a Mueller Hinton Agar plate, in all directions, with a sterile 
swab.  
The excess of moisture was absorbed so that the surface was completely dry before 
applying MIC Test Strip. The strip was applied to the agar surface with the scale facing upwards 
and code of the strip to the outside of the plate, pressing it with sterile forceps on the surface of 
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the agar and ensure that whole length of the antibiotic gradient is in complete contact with the 
agar surface. Once applied, the strip should not be moved. 
 
5. Genotyping methods 
 
5.1. Polymerase Chain Reaction (PCR) 
 
Polymerase chain reaction (PCR) was used to: verify the presence of blaKPC, typing 
assays to investigate the clonal diversity of the isolates and screening for IncFIA plasmids, 
pBK30661 and pBK30683. 
 A DNA suspension was prepared by suspending one or two fresh colonies in 50 μL of 
sterile distilled water. A volume of 1 μL of suspension was added to a final volume of 24 μL 
PCR mixture.  
Generally, PCR reactions were performed in 24 µL reaction mixtures containing 6.25 μL 
of NZYtech 2x Green Master Mix (NZYtech, Portugal), sterile distilled water, reverse primer 
and forward primer. The Master Mix contains deoxyribonucleotides phosphates (dNTPs), 
reaction buffer, MgCl2 and Taq DNA polymerase. The Master Mix have 2.5 mM MgCl2, 200 
µM dNTPs and 0.2 U/ µl DNA polymerase. The primers used for each assay are shown in Table 
1 - Primer sequences for PCRs in this study 
 
A PCR scheme with four duplex PCRs was designed to detect pBK30661-like and 
pBK30683-like plasmids. Duplex I (PCR-1 and PCR-2) was designed to target the IncFIA 
plasmid-specific replication gene repA (in both pBK30661 and pBK30683) and the second 
IncFII replication gene repA in pBK30683. Duplex II (PCR-3 and PCR-4) was designed to target 
the upstream and downstream junctions between Tn4401 and the neigh-boring regions of the 
plasmid. Duplex III (PCR-5 and PCR-6) was designed to detect both junctions of the 68-kb 
integrated fragment in pBK30683. Duplex IV (PCR-7 and PCR-8) was used to detect the 
pBK30661- and pBK30683-associated Tn4401d isoform. pBK30661-like plasmids are positive 
with PCR-1, PCR-3, PCR-4, PCR-6, PCR-7, and PCR-8, while pBK30683-like plasmids are 
positive with all eight PCRs (Figure 5) (Table 1) (Chen et al. 2014).  
In each PCR experiment was used a negative control that differ from the reaction mixture 
by substituting the cell suspension by the same volume of dH2O. 
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Figure 5 - Plasmid structures of pBK30661, pBK30683 and the Tn4401/Tn1331 nested transposon in pBK15692. Light blue shading, shared regions of homology among 
pBK30661, pBK30683, and pBK15692 (Chen et al. 2014) 
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Table 1 - Primer sequences for PCRs in this study 
  
Primer pair Target Primer sequence (5’ - 3’) 
Amplicon size 
(bp) 
Reference 
 
KPC 
KPC_for 
 
KPC_rev 
KPC-1 to KPC-5 
CATTCAAGGGCTTTCTTGCTGC 
 
ACGACGGCATAGTCATTTGC 
538 
(Bouchillon et al. 
2013) 
 BOX-PCR 
BOX A1R generate BOX-PCR profiles CTACGGCAAGGCGACGCTGACG 
 
(Weisburg et al. 1991) 
IncFIA 
 
PCR-1 
 
 
PCR-2 
IA-1f  (a) 
IA-1r  (b) 
 
IA-2f  (c) 
IA-2r (d) 
IncFIA repA of pBK30661 and pBK30683 
 
Second IncFII repA in pBK30683 
GCCGTCCTTTCTGTGACAAATCA 
GGATGGACTGTGGGCACGTT 
 
CCGTTTCTGTGTCATTTGCTCCT 
CTTATAGTGAGACGGCCGGAACC 
516 
 
 
250 
(Figure 5) 
(Chen et al. 2014) 
 
PCR-3 
 
 
 
PCR-4 
 
IA-3f (e) 
IA-3r (f) 
 
IA-4f (g) 
IA-4r (h) 
Tn4401 upstream junction between chrB 
gene and ISKpn6 in both pBK30661 and 
pBK30683 
 
Tn4401 downstream junction between 
Tn4401 tnpR gene and neighboring  
Tn3 tnpA gene in both pBK30661 and 
pBK30683 
   
ATACCGGTGCCGCCATGCTGCG 
TCGTCATGCCGCGGACCACCCC 
 
 
CCGGCATCACCGGCCCTCACCT 
ACACTCCCGGCTGTGCGCCTGA 
213 
 
 
515 
 
PCR-5 
 
 
 
 
PCR-6 
 
IA-5f (i) 
IA-56r (j) 
 
 
 
IA-6f (k) 
 
 
Region between putative cytoplasmic 
protein gene and adenine-specific 
methyltransferase gene (met1) in 
pBK30683 
 
Region between hypothetical protein gene 
and adenine- specific methyltransferase 
gene (met1) in both pBK30661 and 
pBK30683 
 
CGATGACGTGGAGAGCAGTA 
TCCCGAGAATGAATCTGGAC 
 
 
 
CGTGCATTCGGTGACTAAAA 
 
534 
 
 
 
 
768 
 
PCR-7 
 
PCR-8 
 
4401v-r (3781L) (l) 
4401v-r1 (m) 
 
4401v-f (3098U) (n) 
Tn4401d isoform in pBK30661 and 
pBK30683 
CACAGCGGCAGCAAGAAAGC 
GCAAGCCGCTCCCTCTCCAG 
 
TGACCCTGAGCGGCGAAAGC 
 
635 
 
314 
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 PCR was performed in a MyCycler Thermal Cycler (Bio-Rad, USA), with different 
temperature and time for all steps (Table 2). A DNA molecular weight marker, GeneRulerTM 
DNA Ladder Mix - Thermo Fisher Scientific was used as DNA size standard. All primers used 
were ordered from Stab Vida, Portugal or from Sigma, USA.  
 
Table 2 - PCR programs used for amplifications. 
 
The resulting PCR products along with the DNA ladder were loaded in wells of 1.5% 
agarose gel prepared in 1X Tris EDTA (TAE) buffer. Gel electrophoresis was used to separate 
DNA fragments, 90 V for 1 hour for detection blaKPC and IncFIA plasmid, and 90 V for 1 h30 
for genotyping. The gel was then stained with ethidium bromide for 15 minutes and in dH2O for 
10 min and visualized under UV light. Molecular Imager® Gel DocTM XR (Bio-Rad, USA) was 
used to scan the gel.    
 KPC gene Strain typing IncFIA plasmid 
 
Initial denaturation 94℃        5 min 94℃         7 min 95℃            4 min 
Annealing 
94℃       30 seg 
 
55℃       30 seg 
94℃         1 min 
53℃         1 min 
65℃         8 min 
95℃           30 seg 
60℃           30 seg 
72℃            1 min 
x30 
Final extension 72℃        1 min 65℃          16 min 72℃            7 min  
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Abstract: Infectious diseases caused by bacteria are one of the major health problems. 
Moreover, the emergence of β-lactamases, namely, carbapenemases, such as KPC, that confer 
resistance to most β-lactam antibiotics are motive of concern.  The aim of this study was to 
evaluate the presence of blaKPC in strains collected in Centro Hospitalar do Baixo Vouga, E.P.E., 
Portugal, from inpatients and outpatients.  
All the isolates included in this study are non-duplicate and were identified using Gram-
negative bacteria identification card of the automated system VITEK®2 (BioMèrieux, France), 
antimicrobial susceptibility testing (AST) was estimated and advanced expert system (AES) 
rules were taken in consideration. Strains carbapenem resistant were studied by PCR to 
investigate the presence of the blaKPC and typing bacteria. Strains with a positive result in blaKPC 
were further studied to investigate blamcr-1 and IncFIA plasmid. RAPIDEC
® CARBA NP 
(BioMèrieux, France) test was used, according to manufacture’s instructions, to confirm the 
presence of a carbapenemase. 
During the timeframe of this study (2017-2019) a total of 6189 strains were isolated 
among them 61 Enterobacteriaceae and three Pseudomonas aeruginosa exhibited resistance to 
the carbapenems. Fifty-nine strains were recovered from outpatients and five were recovered 
from inpatients. Patients age ranged from 43 to 94 years old. Among all the isolates, Klebsiella 
pneumoniae was the most relevant species since 52 strains were identified. The remaining 
isolates were: five Enterobacter cloacae, one Escherichia coli, one Citrobacter freundii and one 
Enterobacter aerogenes. The PCR was positive for the presence of the blaKPC in 50 of 52 strains, 
which were all Klebsiella pneumoniae. The RAPIDEC® CARBA NP test was positive.  
The strains of K. pneumoniae were divided into 26 clusters, E. cloacae into four different 
clusters and P. aeruginosa into two clusters by BOX-PCR. 
A PCR scheme to detect the distribution of blaKPC-harboring IncFIA (pBK30661-like and 
pBK30683-like) plasmids in the collection of clinical isolates when they present the blaKPC was 
followed. KPC-harboring IncFIA plasmids were found in 27 of 52 K. pneumoniae isolates. 
The results of this study show that in our region, as expected, the blaKPC was prevalent in 
the K. pneumoniae and the majority was transferred in IncFIA plasmid. Nonetheless, the 
percentage of carbapenems resistant Enterobacteriaceae remains low (1 %). Moreover, it is 
extremely important to apply earlier diagnostic techniques, such as molecular techniques, that 
will help to contain the spread more rapidly. 
 
Key-words: carbapenems, carbapenemases, blaKPC, Enterobacteriaceae, Klebsiella 
pneumoniae, Pseudomonas aeruginosa, IncFIA plasmid 
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1. Introduction 
 
Antibiotics are necessary for overall practice of medicine reducing morbidity and 
mortality (Van Hoek et al. 2011; Khan et al. 2018). Nowadays, the number of different 
antimicrobial agents are known is large (Van Hoek et al. 2011). However, β-lactams remain the 
major antibiotic class applied in the treatment of infectious diseases (Moya et al. 2009).  
Carbapenems are widely used because they are a broad spectrum of antibacterial activity 
(Bina et al. 2015). In addition, carbapenems were recommended for the treatment of infections 
caused by multi-drug resistant (MDR) microorganisms (Mohamed et al. 2018).  
However, in the preceding decade, there was an increase in the antimicrobial resistance in 
different pathogens. Microorganisms have several mechanisms that allow them to adapt to stress 
and lead to resistance to several antimicrobials used in clinical practice, for example, strains 
resistant to carbapenems have been isolated (Khan et al. 2018; Mohamed et al. 2018). 
Resistance to carbapenems in Gram-negative bacteria results essentially from a decrease 
in bacterial outer membrane permeability, increased in extended-spectrum β-lactamases 
(ESBLs), AmpC β-lactamases production and carbapenemases (Bina et al. 2015).  
 Carbapenemases are enzymes that hydrolyse carbapenems and are able to break 
penicillins, cephalosporins and monobactams (Logan 2012). In Enterobacteriaceae, these 
enzymes are the most important mechanism of carbapenems resistance. In addition, these are 
high capacity to disseminate, which leads to a high concern in the prevention and transmission of 
these microorganisms (Bina et al. 2015; Bonomo et al. 2018).  
Carbapenemases like KPC, NDM and OXA demand special attention (Bina et al. 2015). 
For example, KPC is the most common enzyme disseminated among Enterobacteriaceae, since 
often are carried on a mobile plasmid. Also, plasmid that mediates NDM has spread quickly 
globally and into that family (Logan 2012). So, carbapenem-resistant Enterobacteriaceae (CRE) 
have become widespread globally and are an urgent public health threat (Khan et al. 2018). 
Moreover, blaKPC are commonly located on Tn4401. blaKPC-3 was part of Tn4401 isoform 
d and located in a cointegrated FIA and FII plasmid. In Portugal, the FIA plasmid was reported 
in clinical isolates, like K. pneumoniae, E. coli, and Enterobacter spp. (Rodrigues et al. 2016; 
Tacão et al. 2017). 
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2. Results and discussion 
2.1. Characterization of bacterial strains 
 
In this study, 64 strains resistant to carbapenems were collected, recovered during 2017 
(N=34), 2018 (N=25), and until March 2019 (N=5).  
Overall samples, the number of strains collected from women (n=37) is higher than 
number of isolates from men (n=27) (Figure 6). 
 
 
 
The patient ages ranged between 43 and 94 years old, being the average age of patients 
with carbapenem- resistant microorganisms 75 years old. These results demonstrate that the 
population with carbapenemase-producing organisms (CPOs) tends to be older and are according 
to Duin and Doi 2017, in the Consortium on Resistance Against Carbapenems in Klebsiella and 
other Enterobacteriaceae (CRACKLE), the average age of patients in the same conditions was 70 
years old (age between 58 to 81 years). 
All the isolates were non-duplicate and recovered from colonization or infections sites: 
urine (n=46), pus (n=9), blood (n=6), sputum (n=2) and tip of the catheter (n=1).  
 
 
 
 
 
Figure 6 - Isolates resistant to carbapenems distributed by gender 
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Following the criteria described in Material and Methods section, 2, the microorganisms 
were classified as nosocomial or non-nosocomial. Overall 64 isolates collected, five were 
nosocomial in different ward of CHBV, whereas 59 were non-nosocomial (Figure 7).  
 
Figure 7 - Distribution of the carbapenemase-producing bacteria considering if they were nosocomial or non-
nosocomial 
The data of this study strengthens an ongoing dissemination of CPOs in community. This 
fact may suggest that cross acquisition and/or a common exogenous source is an important route 
of CPOs acquisition. 
During the period of this study, a total of 64 microorganisms, including 52 K. 
pneumoniae, six E. cloacae, three P. aeruginosa and one E. coli, E. aerogenes and C. freundii 
were suspected to have the blaKPC since they are resistant to carbapenems.  
 
2.2. Detection of blaKPC 
 
2.2.1. Klebsiella pneumoniae 
 
Among 52 K. pneumoniae analysed, the blaKPC was present in 50 of isolates (Figure 8).  
 
 
 
 
 
 
 
Figure 8 - Presence (blaKPC +) or absence (blaKPC -) in K. pneumoniae isolates 
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This fact can justify that resistance to carbapenems, since it is linked to different 
mechanisms, including the production of enzymes like KPC, VIM, IMP, NDM, and OXA- 48 
and among others (Weinstein and Logan 2012; Girmenia et al. 2016).  
  In this study the primers used cover from blaKPC-1 to blaKPC-5 and is describe that genes 
blaKPC-2 and blaKPC-3 account for most of blaKPC. Nonetheless, it not possible to describe the 
positive results in such detail. However, in Portugal, blaKPC-2 was identified only in an 
environmental E. coli isolate in 2010, while blaKPC-3 producers were first detected in 2009 in a 
central hospital. Recently, have been verified widespread distribution of blaKPC-3 among K. 
pneumoniae isolates in different Portuguese hospitals (Rodrigues et al. 2016; Duin and Doi 
2017). 
 
2.2.1.1. Susceptible profile 
 
Among the susceptibility profile for each isolate, special attention was give to last 
resource antibiotics. Taking that in to account the following results were retrieved: the highest 
and lowest resistance was related to piperacillin/tazobactam (n=52/52) and meropenem 
(n=51/52); and colistin (n=5/52), respectively. Intermediate resistance to gentamicin, 
piperacillin/tazobactam and colistin was not observed (n=0/52) and intermediate resistance was 
very low (1.6%) for meropenem (n=1/52), ceftazidime (n=4/52) and cefepime (n=7/52).  
Colistin was the antibiotic with the highest number of susceptible isolates among K. 
pneumonia (n=47/52), on the other hand meropenem, ceftazidime, cefepime and 
piperacillin/tazobactam, exhibited the lowest sensitivity (Table 3).  
 
 
 
Result
MER CFT CP GM PIP/TAZ COL
Resistance 51/52 48/52 45/52 36/52 52/52 5/52
Intermediate 1/52 4/52 7/52 0/52 0/52 0/52
Sensitive 0/52 0/52 0/52 16/52 0/52 47/52
Antibiotic resistant (n/ n total)
Table 3 - Antibiotic resistant by K. pneumoniae isolates. MER: meropenem; CFT: ceftazidime; CP: cefepime; 
GM: gentamicine; PIP/TAZ: piperacillin/tazobactam; COL: colistin 
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Additionally, the presence of blamcr-1, blamcr-3, blamcr-4 and blamcr-5 was accessed by PCR 
method. Among the five isolates that were resistant to colistin (Kp1, Kp11, Kp37, Kp47 and 
Kp44), the gene mcr-1 was shown to be present in one strain (Kp11).  
Also, plasmid IncX-4 was screened in the isolate, but this wasn’t identified (Data not 
show).  
 
2.2.2. Other Enterobacteriaceae 
 
Among all isolates of E. cloacae, E. aerogenes, E. coli and C. freundii the blaKPC was not 
found. Other studies report that for Enterobacter spp., resistance to carbapenems was associated 
with β-lactamase expression (VIM producers are most often found in Italy and Greece) and porin 
deficiency in combination, with a variety of deletion, point mutation, insertional inactivation and 
unknown mechanisms leading to the loss of porin expression (Doumith et al. 2009; Bonomo et 
al. 2018).  
This can be justified since have already been reported in Enterobacteriaceae a class D 
carbapenem-hydrolyzing β-lactamases, namely, blaOXA-48. Nowadays, are acknowledged and are 
increasingly reported worldwide, in many Gram-negative bacteria, including Enterobacteriaceae, 
notably, community E. coli isolates (Djahmi et al. 2014; Bonomo et al. 2018). In addition, OXA-
48-like carbapenemases remain extremely rare as a cause of carbapenem resistance in 
Enterobacteriaceae in the US. However, they are relatively commonly found in Europe, 
especially in Mediterranean countries (Duin and Doi 2017). 
 
 
2.2.3. Pseudomonas aeruginosa 
 
blaKPC was not found in the P. aeruginosa (n=3) isolates as it was expected, since 
metallo-β-lactamases (MBLs) are commonly identified in P. aeruginosa. However, in the 
absence of carbapenemases, the resistance to carbapenems is usually multifactorial: increased 
production of AmpC chromosome-encoded cephalosporinase, reduced outer membrane porin 
OprD expression and associated factors are known to contribute to carbapenem resistance (Poirel 
and Nordmann 2009).  
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2.3. Strain typing: BOX analysis 
 
The clonal composition of 64 isolates was evaluated by BOX-PCR. Among 52 strains of 
K. pneumoniae examined it was possible to identify 26 different banding patterns (1-11 isolates 
each, shown in Figure 9); five different banding types of E. cloacae isolates (1–2 isolates each) 
and two different banding types of P. aeruginosa isolates (1-2 isolates each).  
Sixteen K. pneumoniae isolates exhibited unique genotypes, that confirm the 
discriminatory power of the BOX-PCR technique. This is revealed by Figure 9, which suggests a 
considerable high heterogeneity and genomic diversity between the clinical isolates.  
 
Figure 9 - Isolates of K. pneumoniae grouped by typing, performed by BOX-PCR 
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2.4. Detection of plasmid IncFIA  
 
Strains representative of different clusters and positive for the presence of blaKPC were 
screened for IncFIA plasmids, pBK30661 and pBK30683.  
When one of the plasmids was identified, was considered present in all strains belonging 
the same cluster; the same happens when plasmids were not found. Among 52 isolates of K. 
pneumoniae, the pBK30683 plasmid was found in 27 strains included in 11 different clusters.  
The presence of pBK30683 indicates that blaKPC is located on Tn4401d. These results 
will confirm the role of Tn4401d on the spread of carbapenemase genes among in Portugal, as  
previously verified (Tacão et al. 2017). Acquisition of blaKPC-3 by plasmids from different 
incompatibility groups, like IncFIA, appear to be epidemic and favoured a quick intra- and inter-
species dissemination (Chen et al. 2014; Rodrigues et al. 2016).  
 
3. Conclusion 
 
The recent emergence of CRE is a major threat to hospitalized patients and continues to 
cause serious multidrug-resistant infections around the world (Sartelli et al. 2014). CRE and P. 
aeruginosa have recently increased in some European countries and they frequently harbour 
resistance mediated by carbapenemase production (Sader et al. 2014).   
Carbapenemase genes usually are associated with mobile elements that encode resistance 
to several antibacterial drugs, and consequently produce multi-resistance in strains and 
dissemination interspecies and intraspecies is facilitated. This scenario might predict the 
emergence of drug-resistant phenotypes, likely jeopardizing treatment (Chen et al. 2014; Sader et 
al. 2014; Tacão et al. 2017).  
In this study was verified that blaKPC is the most prevalent among strains.  
Moreover, further studies are required to determine the origins of the pBK30661 plasmid 
and the distributions of this plasmid group in other geographic areas, in order to understand their 
contributions to KPC epidemiology. 
In conclusion, is necessary to reinforce of infection control measures, surveillance, and 
tracking of isolates resistant to carbapenems in clinical institutions, and a coordinated action 
between clinicians, epidemiologists and national reference laboratories for guidance and 
harmonization of protocols.   
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Abstract: 
 
Urinary tract infections (UTIs) and skin and soft tissues infections (SSTIs) are associated 
with considerable levels of morbidity, mortality and leading to an increase in healthcare 
expenditure. In the past two decades has been witnessed an increasing prevalence of resistant 
pathogens in healthcare settings that cause these infections.  
One of the most important mechanisms of resistance is AmpC β-lactamases. These 
cephalosporinases are clinically important, since mediate resistance to commonly used 
antimicrobial agents, like, penicillins and their derivates. They are worrisome since can be 
chromosomally encoded and found in plasmids, leading to their easy dissemination around the 
world. Furthermore, sometimes, in non-nosocomial infections they render the antimicrobial 
empiric therapy improper. 
The aim of the present study was to evaluate the dissemination of AmpC β-lactamases in 
strains from urinary tract and soft tissues infections. Also, it was an objective to infer on the 
origin of these infections.  
A total of 155 strains AmpC-producing Enterobacteriaceae were isolated from patients 
with UTIs and SSTIs in Centro Hospitalar do Baixo Vouga, since September to December 2018. 
Strains resistant to amoxicillin/ clavulanic acid (detected by automated test VITEK®2) were 
selected as it is indicative the presence of blaAmpC. 
In this study, has been verified Klebsiella pneumoniae and Escherichia coli were the 
most common Gram-negative pathogens isolated from UTIs and SSTIs. Others 
Enterobacteriaceae were also present in these infections, such as Enterobacter cloacae, 
Morganella morganii, Klebsiella oxytoca, among others. In addition, most of these infections are 
of non-nosocomial origin. 
This problem leads to complications in choosing the appropriate treatment and it is of 
utmost importance. 
 
Key-words: urinary tract infections, skin and soft tissues infections, AmpC β-lactamases, 
dissemination, cephalosporinases, Enterobacteriaceae, Gram-negative microorganisms, non-
nosocomial 
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1. Introduction 
 
Urinary tract infections are the most common infection both in the younger and older 
population. In 2010, the UTIs was the fourth foremost reason for hospital admission in older 
patients, followed heart failure, pneumonia and septicemia (Ma and Hughes 2018). There are 
several diseases associated with a urinary tract that encompasses infections from simple cystitis 
involving the bladder to the entire urinary tract, including renal pelvis and kidney 
(pyelonephritis) (Smirnov and Egbert 2016).  
Skin and soft tissues infections (SSTIs) are amongst the most common bacterial 
infections in humans and represent about 10% of hospital admissions in the US. SSTIs has a 
broad range of etiology, clinical manifestation and severity (Eckmann and Dryden 2010). The 
skin and soft tissues infection in hospitalized patients contributes to prolonged length of stay, 
leading to increase costs of medical care and antimicrobial resistance emergence (Moet et al. 
2007). Both, the skin and soft tissue is a resistant, flexible and structural barrier to invasion. 
Ruptures in skin, like ulcers and surgical or traumatic wounds, allow colonization with a broader 
range of bacteria, which can progress in inflammation of surrounding areas - soft tissues. In other 
words, skin and soft tissue infections are related microbial invasions in epidermis, dermis and 
subcutaneous tissues and can be potentially fatal (Dryden 2009, 2010).  
Most prevalent microorganisms in UTIs are E. coli (75%-95% of events), followed by 
Pseudomonas aeruginosa, Klebsiella spp., Enterobacter species and Acinetobacter baumannii. E. 
coli strains infect urinary tract through a variety of mechanisms, including special adhesions, 
fimbriae, biofilm and aversion of host responses (Peleg and Hooper 2012; Ma and Hughes 
2018).  
On the other hand, almost all microorganisms are able to cause SSTIs, but the major 
microorganism involved is Staphylococcus aureus, followed by P. aeruginosa, E. coli and 
Enterococcus spp. (Dryden 2009). 
For optimal treatment of these infections is necessarily know pathophysiology, awareness 
of microorganisms that cause infection, find adequate antibiotic therapy and if necessaire reaches 
for surgical intervention (Dryden 2010; Ma and Hughes 2018).  
As mentioned above, Gram-negative microorganisms are associated of UTIs and SSTIs; 
and are highly efficient in the acquisition of drug resistance mechanisms, namely, β-lactamases 
that destroy the β-lactam ring (Llarrull et al. 2010; Peleg and Hooper 2012). In addition, has been 
reported an increase in the number of drug-resistant organisms that cause SSTIs in both hospital- 
and community-acquired (Eckmann and Dryden 2010). 
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AmpC β-lactamases are clinically important cephalosporinases since they mediate 
resistance to most penicillins, some cephalosporins, some narrow-spectrum β-lactams and β-
lactam/ β-lactamase inhibitor combinations (Jacoby 2009; Harris 2015; Iredell et al. 2016). 
Initially, blaAmpC has been described only in chromosome, but nowadays blaAmpC is present in 
plasmids and has the ability to transfer between them and it dissemination is observed worldwide 
(Bush et al. 1995; Jacoby 2009; Maseda et al. 2014). So, microorganisms with potential for 
production AmpC β-lactamases may lead to multidrug resistance, which difficult the selection of 
an effective antibiotic and treatment (Jacoby 2009). 
β-lactam/ β-lactamase inhibitors are used for empiric treatment of UTIs and SSTIs. 
However, some β-lactamases inhibitor enhance the expression of the AmpC, such as clavulanic 
acid, in other words, AmpC β-lactamases are inducible by clavulanic acid (Jacoby 2009). 
Empiric antimicrobial therapy was inappropriate in more than 30% of the cases of an infection 
caused by a pathogen identified to be an AmpC-producer (Conen et al. 2015).  
Cefepime, ceftolozane and carbapenems are stable against AmpC β-lactamases therefore 
can be used to treat these type of infections (Jacoby 2009; Khan et al. 2018). 
 
2. Results and discussion 
 
2.1. Bacterial strains characterization of urinary tract infections  
 
In this study, 133 Enterobacteriaceae with AmpC were collected from a positive 
uroculture.  
Among all samples, the number of urine samples retrieved from women (n=76) is higher 
than number of isolates from men (n=57) (Figure 10), which is in agreement with the studies 
performed by Mendo et al. 2008 and Costa et al. 2009.  
 
 
 
 
 
 
 
 Figure 10 - Urinary tract infection distributed by gender. 
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This result can be explained by the structural or functional differences of the urinary tract 
between men and women, such as, length of the urethra and its close proximity to the vagina. 
Also due to sexual activity, gestation and menopause. On other hand, UTIs are less frequent in 
males given that they possess a longer urethra and due to the antibacterial action of prostatic 
liquid. When these infections occur they may be connected to complex problems such as prostate 
obstructions, vesicular calculus, catheterization and diabetes (Mendo et al. 2008). 
 
The distribution of the strains collected by age shows that 68% are 65 years of age or 
older (90/133 isolated), 15% are between 19 and 64 years old (20/133) and 17% of the 
population are less than 30 years (23/133 isolated) (Figure 11). The youngest is one week old 
and eldest has 97 years old, demonstrating high heterogeneity in the group of individuals under 
study regarding age.  
 
 
 
 
 
 
 
 
The incidence was higher in patients with 65 years of age or older. This can be explained, 
due to the increase in the immune systems weakness, possible limitations of hygiene habits and 
anatomical-functional alterations of the bladder between men and women, such as partial 
obstruction of the urinary tract, manipulation, reduction of urinary flow and anomalies (Mendo et 
al. 2008; Costa et al. 2009; Narciso et al. 2011). 
 
 
 
 
 
 
Figure 11 - Distribution of the strains collected by age in urinary tract infections 
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Following the criteria described in Material and Methods section, 2, the microorganisms 
were classified as nosocomial or non-nosocomial. Overall 133 isolates collected, 42 were 
nosocomial in different ward of CHBV, whereas 91 were non-nosocomial (Figure 12). 
 
The study reported by Bouchillon et al. 2013, describes the same trend, among 2,135 
Gram-negative isolates, the number of hospital-acquired (HA) isolates is lower (20%) than 
community-acquired (CA) isolates (66%). These results can be explained on the basis of an 
erroneous empirical treatment that leads to their successful spread in the community (Conen et 
al. 2015). 
Among all isolated species, K. pneumoniae (n=58) and E. coli (=57) were the most 
common pathogens isolated from urine, followed by E. cloacae (n=8), Morganella morganii 
(n=4), K. oxytoca (n=2) and E. aerogenes (n=2); and Serratia marcescens (n=1) and C. freudii 
(n=1), as shown in Figure 13.  
 
 
 
 
 
 
 
 
 
Figure 13 - Distribution of different strains probably caused urinary tract infections, among all isolates tested positive for AmpC 
expression 
Figure 12 - Distribution of the UTIs isolates considering if they were nosocomial or non-nosocomial 
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Uropathogenic identified in this study were similar to those of many other studies.  
According to other studies E. coli was the most frequently isolated pathogen causing UTIs, 
followed K. pneumoniae. As well as, other Enterobacteriaceae species, including C. freundii, C. 
koseri, E. aerogenes, M. morganii and S. marcescens, P. mirabilis, P. aeruginosa,  K. oxytoca 
and E. cloacae (Bouchillon et al. 2013; Morrissey et al. 2013; Jean et al. 2016; Salleh et al. 
2017).  
 
In the present study, the carriage of an AmpCs alone (n=70), both an AmpCs and an 
ESBL (n=45) and both an AmpCs and CPOs (n=18) was analysed (Figure 14).  
 
Among 113 strains with AmpCs, 45 was confirmed to also produce extended-spectrum β-
lactases (ESBLs), namely, K. pneumoniae (30/45), E. coli (14/45) and K. oxytoca (1/45) (Figure 
15).  
      
     
Figure 14 - Distribution of combined resistance mechanisms among AmpCs positive strains 
Figure 15 - Distribution of strains producer both AmpC and ESBL. 
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According to Jacoby 2009, most of the times organisms producing AmpC β-lactamases 
are also positive ESBLs. In addition, according to Bouchillon et al. 2013, ESBLs rates were 
10.3% of K. pneumoniae, 6.8% of E. coli, 11.1% of K. oxytoca and 3.7% of P. mirabilis isolates. 
These strains are very important since ESBL-producing K. pneumoniae was associated with a 
higher rate of treatment failure 72h after the initiation of treatment when compared with non-
ESBL (Kang et al. 2004). 
Also, in this study we analysed the number of isolates carrying a combination of an 
AmpCs with CPOs. Among 113 Gram-negative strains collected with AmpCs, 17 K. 
pneumoniae and one E. cloacae were resistant to carbapenems.  
 
 
2.2. Bacterial strains characterization of skin and soft tissues infections 
 
In this study, were collected 42 Enterobacteriaceae with AmpC, form soft tissues 
infections. 
 
Figure 16 shows the analysis of the distribution of the strains, that cause or probably 
caused SSTIs, collected by gender. It was observed the number of strains were isolated from 
sputum samples retrieved from men (n=23) is higher than a number of isolates from women 
(n=19).  
19
23
Female
Male
 
                        Figure 16 - Skin and soft tissues infections distributed by gender. 
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The distribution of the strains collected by age shows that 32/42 of isolated are 65 years 
of age or older, 8/42 strains are between 30 and 64 years old and 2/42 isolates of the population 
are less than 30 years (Figure 17). The youngest patient has two years and the eldest has 89 years 
old. Once again, these results demonstrate a high heterogeneity in the group of individuals under 
study regarding age. A study carried out by (Suaya et al. 2013) shows that SSTIs and their 
associated complications were more common in the population aged 65 years and older. 
 
              Figure 17 - Distribution of the strains collected by age in soft tissues infections 
 
Following the criteria described in Material and Methods section, 2, the microorganisms 
were classified as nosocomial or non-nosocomial. Overall 42 isolates collected, 40 were non-
nosocomial in different ward of CHBV, whereas two were nosocomial (Figure 18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 - Distribution of the SSTIs isolates considering if they were nosocomial or non-nosocomial. 
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Among all 42 isolated species, K. pneumoniae (n=14) and E. coli (=14) were the most 
common pathogens causing SSTIs, followed by E. cloacae (n=6), M. morganii (n=2) and K. 
oxytoca (n=2) and E. aerogenes (n=1), C. freudii (n=1), Citrobacter braaki (n=1) and Serratia 
marcescens (n=1). This is represented in Figure 19. 
 
 
Figure 19 - Distribution of different strains, that probably caused SSTIs, among all isolates tested positive for AmpC 
expression 
 
According to SENTRY Antimicrobial Surveillance Program, since 1998 to 2004, in 
Europe, the most microorganisms present in SSTIs are S. aureus, followed by P. aeruginosa, E. 
coli, Enterococcus spp., Enterobacter spp., coagulase-negative Staphylococci, β-Streptococcus, 
Klebsiella spp., P. mirabilis and at last Acinetobacter spp. So, the most Enterobacteriaceae found 
are E. coli, Enterobacter spp., Klebsiella spp., P. mirabilis and Acinetobacter spp. (Moet et al. 
2007).  
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In the present study, the carriage of an AmpCs alone (n=25), both an AmpCs and an 
ESBLs (n=11) and both an AmpCs and CPOs (n=6) was analysed (Figure 20).  
 
Figure 20 - Distribution of combined resistance mechanisms among AmpC positive strains 
 
In this study, among 42 strains with AmpCs, 11 was confirmed to produce extended-
spectrum β-lactases (ESBLs), namely, K. pneumoniae (7/11) and E. coli (4/11) (Figure 21).  
 
Figure 21 - Distribution of strains producer both AmpCs and ESBL 
 
Several studies show that infections caused by ESBL-producing E. coli and K. 
pneumoniae have a significant impact on clinical outcome and are an emerging problem in 
ambulatory settings.  For example, when was evaluated the effect of ESBL-producing E. coli and 
K. pneumoniae infection on clinical outcome, these were associated with a higher hospital rate 
(Caínzos 2008). The Infectious Diseases Society of America (IdSa) identified ESBL-producing 
 Chapter II. Dissemination of AmpCs in Isolates Causing Urinary Tract Infections and Skin and Soft Tissues 
Infections in Centro Hospitalar do Baixo Vouga 
 
53 
 
Enterobacteriaceae as problematic pathogens which will continue to compromise therapy for 
SSTIs (Moet et al. 2007; Eckmann and Dryden 2010). 
 
In this study, among 42 Gram-negative strains collected with AmpCs, five K. 
pneumoniae and one E. aerogenes were resistant to carbapenems.  
 
3. Conclusion 
 
Urinary tract infections and skin and soft tissues infection are one of the causes of 
significant morbidity and mortality in the hospitals, leading to an economic burden (Caínzos 
2008; Smirnov and Egbert 2016). In addition, an increased global prevalence of multi-drug 
resistant pathogens leads to complication in the antibiotic selection process. For examples, many 
times, the antimicrobial therapy is inappropriate when the infections are caused by a pathogen 
AmpC producer that lead to failure in treatments (Caínzos 2008; Eckmann e Dryden 2010; 
Conen et al. 2015). 
The results obtained in the present study are worrisome since the species isolated are 
AmpC producer. These microorganisms have the ability to develop resistance during 
antimicrobial therapy with β-lactam antibiotics, like carbapenems and zwitterionic (sometimes 
referred to as fourth generation) cephalosporins (e.g., cefepime) (Thomson 2010). In addition, 
were observed that these infections caused by microorganisms are both nosocomial and non-
nosocomial. This is more worrisome since the spread in community is higher.  
In an attempt to solve this problem is of utmost importance choose new empirical 
regiments taking advantage of potent antibiotics or to develop new classes of antibiotics that are 
effective against these problems. 
The control of the spread of multiply antibiotic-resistant pathogens is difficult. To 
improve it, laboratories should be able to detect AmpC β-lactamases since the diagnostic 
microbiology is essential to quality initiatives in hospitals. Furthermore, is necessary the 
development of new microbiological methods to simplify rapid and reliable detection of blaAmpC 
plasmid carriers.  
Finally, is essential to continue monitoring these microorganisms to understand the trends 
in pathogens occurrences in hospitals and community and monitoring the resistance to 
antimicrobials commonly used. These programs, like SENTRY, are fundamental to modify the 
prescription locals guidelines and the infection control interventions if necessaire (Moet et al. 
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2007). This infection control can prevent additional infections and the spread of resistant 
pathogens (Thomson 2010). 
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Abstract: 
 
Ceftolozane/tazobactam (Ceft/Taz) is a new antibiotic resulting from the combination of 
a novel cephalosporin, structurally similar to ceftazidime, with tazobactam, a well-known β-
lactamase inhibitor. 
To evaluate the activity of this antimicrobial against Enterobacteriaceae and 
Pseudomonas aeruginosa, 44 non-duplicate Enterobacteriaceae and three P. aeruginosa clinical 
isolates were consecutively collected during the period from September to November 2018, from 
patients in Centro Hospitalar do Baixo Vouga with intra–abdominal infections.  
Antimicrobial susceptibility testing was performed with the MIC Test Strip. Results were 
interpreted according to EUCAST criteria. Ceft/Taz showed good activity against almost all 
isolates (46/47), with MIC50 values comprising ≤0.38 and ≤4.00 µg/mL.  
In conclusion, Ceft/Taz exhibited, in vitro, potent activity against Enterobacteriaceae and 
P. aeruginosa, including isolates that were multi-drug resistant, extended-spectrum β-lactamases 
producers, carbapenemases producers and AmpCs positive phenotype. Ceft/Taz has the potential 
to become a useful addition to the limited armamentarium of drugs that can be used to treat these 
problematic pathogens and has been recently approved for the treatment of complicated intra-
abdominal infections. 
 
Keywords: intra-abdominal infections, Enterobacteriaceae, Pseudomonas aeruginosa, 
AmpCs, extended-spectrum β-lactamases  
 
1. Introduction 
 
Intra-abdominal infections (IAIs) encompass a broad spectrum of pathological 
conditions, ranging from uncomplicated appendicitis to fecal peritonitis. According to the clinic, 
IAIs are subdivided into two main categories, uncomplicated and complicated (cIAIs) infections. 
Uncomplicated infections are located only in an organ and do not spread to the peritoneum, 
while cIAIs extends into more than one organ and causes peritonitis, which increases mortality 
rates (Sartelli et al. 2013; Eckmann and Solomkin 2015).  
The most common pathogens involved in IAIs are Enterobacteriaceae, namely, 
Escherichia coli, Klebsiella pneumoniae and Enterobacter spp. and the treatment of these type of 
infections involves antimicrobial therapy (Maseda et al. 2014; Sartelli et al. 2014). 
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In mid-nineties, 95-97% of the microorganisms associated with IAIs were susceptible to 
commonly used antibiotics. However, microorganisms developed resistance against the drugs, 
due to excessive use of antimicrobials. For example, Gram-negative organisms exhibit resistance 
to β-lactams and co-resistance other antibiotics (Maseda et al. 2014). 
Nowadays, it has been reported an increased number of MDR in IAIs and this type of 
infections are a global problem that requires utmost attention. IAIs caused by MDR were 
associated with longer duration of inadequate antimicrobial therapy and hospital length of stay, 
higher access to intensive care unit (ICU) and re-laparotomy. These factors lead to higher 
hospitalization costs, lower quality of care and increased morbidity and mortality. Recent 
exposure to antimicrobial agents (previous 90 days) was considered a risk factor for resistance. 
However, the presence of severe cardiovascular disease, leukocytosis or leukopenia, hospital-
acquired infections, inadequate source control of the infection wasn’t associated with risk of 
isolating MDR pathogens (Maseda et al. 2014; Labricciosa et al. 2018; Mohamed et al. 2018). 
Ceftolozane/tazobactam (Ceft/Taz) is a new antibiotic resulting from the combination of 
a novel cephalosporin of the third generation with a β-lactamase inhibitor (Mohamed et al. 
2018).  
Ceftolozane (Figure 22) (previously CXA-101 and FR-264205) is structurally similar to 
ceftazidime. Ceftazidime is a third-generation cephalosporin and has been used for the treatment 
of Gram-negative infections for more than 20 years.  
However, β-lactams, such as ceftazidime and cefotaxime, in presence of some PBPs are 
unstable since they increase the induction of AmpCs. So, at position 3 of the cephem nucleus of 
the new cephalosporin, the side-chain is modified (Moyá et al. 2010; Eckmann and Solomkin 
2015; Giacobbe et al. 2018; Sebaaly et al. 2018; Sheu et al. 2018).  
 
Figure 22 - Chemical structure of ceftolozane. Adapted by (Sebaaly et al. 2018). 
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A heavier chain, pyrazole, in ceftolozane, replaces the pyridinium found in ceftazidime. 
The presence of the pyrazole ring in ceftolozane gives it a steric hindrance, i.e., it prevents the 
binding of a novel binding, for example, β-lactamases. In this way, the hydrolysis of the 
compound is prevented, providing stability against the excessive production of AmpC β-
lactamases produced by P. aeruginosa. In contrast, in case of ceftazidime, the pyridinium ring 
present confers a lower activity (Moyá et al. 2010; Eckmann and Solomkin 2015; Giacobbe et al. 
2018; Sebaaly et al. 2018; Sheu et al. 2018). 
In addition, ceftolozane have the aminothiadiazole ring at 7-position of the cephem 
nucleus of ceftolozane and that provide increased activity against Gram-negative bacilli when 
compared to other cephalosporins (Eckmann and Solomkin 2015). 
 
Furthermore, ceftolozane inhibits penicillin-binding proteins (PBPs). For example, 
ceftolozane binds with high affinity to three essential PBPs of E. coli (PBP1a/b, PBP1b and 
PBP3) and also P. aeruginosa, inhibiting them (Eckmann and Solomkin 2015). 
Like others oxyimino-cephalosporins, the activity of ceftolozane is compromised by 
extended-spectrum β-lactamases (ESBLs), depressed AmpC enzymes and carbapenemases 
(Livermore et al. 2010). 
 
Tazobactam (Figure 23) is a well-known β-lactamase inhibitor. It inhibits most β-
lactamases, including the most common ESBLs, such as CTX, SHV, TEM and the class C 
cephalosporinases. Tazobactam binds irreversibly to β-lactams and leads to slow hydrolysis. On 
the other hand, the ESBLs TEM-3–9, SHV-2–4, OXA-2, and CTX-M-3–18 reduce the activity 
of the tazobactam, but it may still remain effective (Sebaaly et al. 2018; Sheu et al. 2018). 
 
Figure 23 - Chemical structure of tazobactam. Adapted by (Sebaaly et al. 2018) 
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Therefore, the combination between ceftolozane and tazobactam increases the activity 
against many ESBL-producing Enterobacteriaceae and MDR P. aeruginosa. Ceft/Taz has the 
most potent antipseudomonal activity compared (Eckmann and Solomkin 2015). 
Ceft/Taz exhibits excellent in vitro activity against Gram-negative microorganisms 
isolated from IAIs, UTIs and bloodstream infections, even when there are ESBL-producing 
microorganisms (Titelman et al. 2011; Ma and Hughes 2018; Sheu et al. 2018). For this reason, 
Ceft/Taz is an alternative to carbapenems for the treatment of infections caused by ESBLs 
microorganisms isolated from IAIs (Giacobbe et al. 2018; Sheu et al. 2018). For all the above, 
recently, Ceft/Taz has been approved for the treatment of cIAIs, by the U.S. Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) (Giacobbe et al. 2018). 
The main purpose of this study was to evaluate the in vitro activity of Ceft/Taz against 
ESBL-producing Enterobacteriaceae and MDR P. aeruginosa using a MIC test strip. 
 
2. Results and Discussion 
 
2.1. Bacterial strains characterization 
 
During the period of this the study, a total of 47 microorganisms, including 44 
Enterobacteriaceae and three P. aeruginosa, suspected to cause intra-abdominal infections were 
studied. As previously reported by other studies Enterobacteriaceae were found to be the most 
common bacteria involved in IAIs (Sartelli et al. 2014). 
 
Among Gram-negative bacteria, the most frequent microorganism isolated was E. coli 
(24/47 total), followed by K. pneumoniae (10/24 total), Enterobacter cloacae (5/47) and 
Pseudomonas aeruginosa (3/47). The remaining strains, Citrobacter freudii, Klebsiella oxytoca, 
Morganella morganii, Enterobacter aerogenes and Enterobacter asburiae are present in the 
ration of 1/47 (Figure 24). 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 - The different strains and our quantitative from IAIs 
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Following the criteria described in Material and Methods section, 2, the microorganisms 
were classified as nosocomial or non-nosocomial. Overall 47 isolates collected, five were 
nosocomial in different wards of CHBV, whereas 42 were non-nosocomial (Figure 25). 
According to Sartelli et al. 2014, verified the same: 86.7% of patients were affected by 
community-acquired IAIs while the remaining 13.3% suffered from healthcare-associated 
infections. 
 
 
 
In our study, all P. aeruginosa (n=3) were nosocomial. According to Sartelli et al. 2014, 
P. aeruginosa is one of the major nosocomial pathogens in the world. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 - Distribution of the IAIs isolates considering if they were nosocomial and non-nosocomial 
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2.1.1. Extended-Spectrum β-lactamases producing Enterobacteriaceae  
 
Screen-positive for the ESBL phenotype was confirmed in 13 microorganisms; E. coli 
(5/24) and K. pneumoniae (8/10). These results are demonstrated in Figure 26.  
 
 
 
 
 
 
 
 
 
 
 
Figure 26 - Number of ESBL-producing microorganisms; Escherichia coli (5/24) and Klebsiella pneumoniae (8/10) 
 
This is according to  Sheu et al. 2018, which verified that K. pneumoniae and E. coli are 
the two most common species of the family Enterobacteriaceae ESBL producers.  
Analysing the figure is evident that the number of ESBL-positive K. pneumoniae is 
higher than ESBL-positive E. coli isolates. These results are in accordance to those studies 
reported by Sheu et al. 2018, since ESBL-positive K. pneumoniae isolates comprised 42.8% of 
all identified K. pneumoniae isolates, while ESBL-positive E. coli isolates made up 20.6% of all 
identified E. coli isolates.  
In this study, ESBL-positive Enterobacteriaceae were more prevalent in inpatients 
(10/13) than in outpatients (3/13), and this is according to Sartelli et al. 2014.  
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2.1.2. Multi-drug resistant Gram-negative 
 
Among all isolates, eighteen were MDR organisms (18/47) were isolated, namely, E. coli 
(7/24), followed by K. pneumoniae (8/10), E. cloacae (2/5) and M. morganii (1/1). The 
remaining microorganisms (P. aeruginosa, C. freudii, K. oxytoca and E. asburiae) did not 
present multi-drug resistant phenotype as shown in Figure 27. 
 
 
 
 
 
Fourteen MDR organisms were recovered from inpatients, while only four were 
recovered from outpatients. Our findings are in accordance with those previously described by 
Labricciosa et al. 2018, since, in this multi-center study, was found a significant difference 
between MDR organisms that were isolated from health-acquired and community-acquired 
infections, those being more frequent in the first group. 
Figure 27 - Strains of MDR microorganisms 
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2.2. Antimicrobial susceptibility testing  
 
From a total of 47 microorganisms, 46 were susceptible to Ceft/Taz and only one K. 
pneumoniae presented an intermediate phenotype. In other words, the overall susceptibility of E. 
coli, E. cloacae, E. aerogenes, C. freundii, K. oxytoca, M. morganii, E. asburiae and P. 
aeruginosa to ceftolozane/tazobactam was 100%. 
Ceftolozane/tazobactam showed good activity against E. coli (n=24) with MIC50 values 
of 0.5 µg/ mL in 15 of 24 isolates tested and K. pneumoniae (n=10), with MIC50 values of 1.00 
µg/ mL in four of ten isolates tested. Ceft/Taz also demonstrated good activity against other 
frequently isolated Enterobacteriaceae, such as, E. aerogenes (MIC50 1.50 µg/ mL, n=1), C. 
freundii (MIC50 0.38 µg/ mL, n=1), K. oxytoca (MIC50 0.50 µg/ mL, n=1), M. morganii 
(MIC50 0.50 µg/ mL, n=1), E. cloacae (MIC50 0.50 µg/ mL, n=5), E. asburiae (MIC50 0.50 µg/ 
mL, n=1); and P. aeruginosa (MIC50 0.75 µg/ mL, n=1; MIC50 1.00 µg/ mL, n=1; MIC50 1.50 
µg/ mL, n=1). The MIC50 values for all strains isolated in IAIs showed in Table 4 
The results of this study confirm previous studies was tested the activity of ceftolozane-
tazobactam, in vitro, against P. aeruginosa (Shortridge et al. 2018).  
 
 
 
 
 
 
0,38 0,50 0,75 1,00 1,50 2,00 3,00 4,00
Enterobacter aerogenes - - - - 1 - - -
Escherichia coli 4 15 2 1 - 1 1 -
Citrobacter freundii 1 - - - - - - -
Klebsiella oxytoca 1 - - - - - - -
Morganella morganii - 1 - - - - - -
Klebsiella pneumoniae 1 1 1 4 1 1 - 1
Enterobacter cloacae - 5 - - - - - -
Enterobacter asburiae - 1 - - - - - -
Pseudomonas aeruginosa - - 1 1 1 - - -
MIC50 values of susceptibility for differents microorganisms (µg/mL)
Table 4 - MIC50 values of susceptibility for Enterobacteriaceae (Enterobacter aerogenes, Esherichia coli, Citrobacter 
freudii, Klebsiella oxytoca, Morganella morganii, Klebsiella pneumoniae, Enterobacter cloacae and Enterobacter asburiae) and 
Pseudomonas aeruginosa 
 
Table 4 - MIC50 values of susceptibility for Escherichia coli isolate with ESBL screen-positive phenotype and non-ESBL 
phenotype.Table 5 - MIC50 values of susceptibility for Enterobacteriaceae (Enterobacter aerogenes, Esherichia coli, Citrobacter 
freudii, Klebsiella oxytoca, Morganella morganii, Klebsiella pneumoniae, Enterobacter cloacae and Enterobacter asburiae) and 
Pseudomonas aeruginosa 
 
Table 6 - MIC50 values of susceptibility for Escherichia coli isolate with ESBL screen-positive phenotype and non-ESBL 
phenotype. 
 
Table 7 - MIC50 values of susceptibility for Klebsiella pneumoniae isolates with ESBL screen-positive phenotype and non-
ESBL phenotype.Table 8 - MIC50 values of susceptibility for Escherichia coli isolate with ESBL screen-positive phenotype and non-
ESBL phenotype.Table 9 - MIC50 values of susceptibility for Enterobacteriaceae (Enterobacter aerogenes, Esherichia coli, Citrobacter 
freudii, Klebsiella oxytoca, Morganella morganii, Klebsiella pneumoniae, Enterobacter cloacae and Enterobacter asburiae) and 
Pseudomonas aeruginosa 
 
Table 10 - MIC50 values of susceptibility for Escherichia coli isolate with ESBL screen-positive phenotype and non-ESBL 
phenotype.Table 11 - MIC50 values of susceptibility for Enterobacteriaceae (Enterobacter aerogenes, Esherichia coli, Citrobacter 
freudii, Klebsiella oxytoca, Morganella morganii, Klebsiella pneumoniae, Enterobacter cloacae and Enterobacter asburiae) and 
Pseudomonas aeruginosa 
 
Table 5 - MIC50 values of susceptibility for Escherichia coli isolate with ESBL screen-positive phenotype and non-ESBL 
phenotype. 
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2.2.1. Extended-Spectrum β-lactamases producing Enterobacteriaceae  
 
From a total of 24 E. coli, five isolates were positive for ESBL phenotype, nonetheless, 
all were susceptible to Ceft/Taz, which demonstrated potent activity (≤0.50 and ≤3.00 µg/mL). 
All non-ESBLs phenotype isolates were inhibited with Ceft/Taz that exhibited a potent activity 
(≤0.38 and ≤2.00 µg/mL). These values were demonstrated in Table 5. 
 
 
 
 
 
 
 
From a total of ten K. pneumoniae, eight isolates exhibited an ESBL phenotype (n=8), 
which were susceptible to Ceft/Taz (≤0.38 and ≤1.50 µg/mL). All isolates non-ESBL phenotype 
were inhibited by Ceft/Taz and the activity is ≤0.50 and ≤4.0 µg/mL. These values were 
demonstrated in Table 6. 
.
   
 
 
 
 
 
The results of this study confirm previous studies where the activity of Ceft/Taz, in vitro, 
against Enterobacteriaceae, including those with extended-spectrum β-lactamases, was tested 
(Shortridge et al. 2018). 
 
 
 
 
 
0,38 0,75 1,00 1,50 2,00 0,50 4,00
1 1 4 1 1 1 1
ESBLs producer non-ESBLs producer
Klebsiella pneumoniae
MIC50 values of susceptibility for differents microorganisms (µg/mL)
Table 6 - MIC50 values of susceptibility for Klebsiella pneumoniae isolates with ESBL screen-positive 
phenotype and non-ESBL phenotype. 
 
Table 52 - MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates.Table 53 - 
MIC50 values of susceptibility for Klebsiella pneumoniae isolates with ESBL screen-positive phenotype and non-
ESBL phenotype. 
 
Table 54 - MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates. 
 
Table 55 - MIC50 values of susceptibility for MDR and non MDR Klebsiella pneumoniae isolates.Table 56 
- MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates.Table 57 - MIC50 values of 
susceptibility for Klebsiella pneumoniae isolates with ESBL screen-positive phenotype and non-ESBL phenotype. 
 
Table 58 - MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates.Table 59 - 
MIC50 values of susceptibility for Klebsiella pneumoniae isolates with ESBL screen-positive phenotype and non-
ESBL phenotype. 
 
Table 7 - MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates. 
 
Table 60 - MIC50 values of susceptibility for MDR and non MDR Klebsiella pneumoniae isolates.Table 61 
- MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates. 
Table 5 - MIC50 values of susceptibility for Escherichia coli isolate with ESBL screen-positive phenotype 
and non-ESBL phenotype. 
 
Table 28 - MIC50 values of susceptibility for Klebsiella pneumoniae isolates with ESBL screen-positive 
phenotype and non-ESBL phenotype.Table 29 - MIC50 values of susceptibility for Escherichia coli isolate with ESBL 
screen-positive phenotype and non-ESBL phenotype. 
 
Table 30 - MIC50 values of susceptibility for Klebsiella pneumoniae isolates with ESBL screen-positive 
phenotype and non-ESBL phenotype. 
 
Table 31 - MIC50 values of susceptibility for MDR  non MDR Escherichia coli isol tes.Table 32 - 
MIC50 values of susceptibility for Klebsiella pneumoniae isolates with ESBL screen-positive phenotype and non-
ESBL phenotype.Table 33 - MIC50 values of susceptibility for Escherichia coli isolate with ESBL screen-positive 
phenotype and non-ESBL phenotype. 
 
Table 34 - MIC50 values of susceptibility for Klebsiella pneumoniae isolates with ESBL screen-positive 
phenotype and non-ESBL phenotype.Table 35 - MIC50 values of susceptibility for Escherichia coli isolate with ESBL 
screen-positive phenotype and non-ESBL heno pe. 
 
Table 6 - MIC50 values of susceptibility for Klebsiella pneumoniae isolates with ESBL screen-positive 
phenotype and non-ESBL phenotype. 
 
Table 36 - MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates.Table 37 - 
MIC50 values of susceptibility for Kl bsiel a pneumoniae isolates with ESBL screen-positiv phenotype and non-
ESBL phenotype. 
 
Table 38 - MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates. 
 
Table 39 - MIC50 values of susceptibility for MDR and non MDR Klebsiella pneumoniae isolates.Table 40 
- MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates.Table 41 - MIC50 values of 
susceptibility for Klebsiella pneumoniae isolates with ESBL screen-positive phenotype and non-ESBL phenotype. 
 
Table 42 - MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates.Table 43 - 
MIC50 values of susceptibility for Kl bsiel a pneumoniae isolates with ESBL screen-positiv phenotype and non-
ESBL ph notype.Table 5 - MIC50 v lues f susceptibility for Escherichia coli isolate with ESBL screen-positive 
phenotype and non-ESBL phenotype. 
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2.2.2. Multi-drug resistant Gram-negative 
 
In this study, seven E. coli and eight K. pneumoniae strains present multi-drug resistance 
phenotype. 
When Ceft/Taz was tested against MDR E. coli isolates (7/24), they were all susceptible 
to this antimicrobial that demonstrated a potent activity (≤0.50 and ≤3.00 µg/mL). Also, all non-
MDR E. coli isolates (n=17) were inhibited by Ceft/Taz, which once again exhibited a potent 
activity (≤0.38 and ≤2.00 µg/mL). These results are demonstrated in Table 7. 
 
 
 
 
 
 
 
 
Considering MDR K. pneumoniae isolates (8/10), all the isolates tested were susceptible 
to ceftolozane/tazobactam with MIC50 values ranging ≤0.38 and ≤2.00 µg/ mL. Also MDR K. 
pneumoniae isolates were positive for ESBL phenotype screen. All non-MDR K. pneumoniae 
isolates (n=2) were inhibited by Ceft/Taz and the MIC50 values ranged from ≤0.50 to ≤4.00 µg/ 
mL. These results were demonstrated in Table 8. 
 
 
 
 
 
 
 
It should be noted that all strains were AmpC–producing isolates. When tested, 
ceftolozane/tazobactam was active, in vitro, against these isolates, with MIC50 values of ≤0.38 
and ≤4.0 µg/ mL. 
 
 
 
 
0,50 1,00 3,00 0,38 0,50 0,75 2,00
5 1 1 4 10 2 1
MIC50 values of susceptibility for differents microorganisms (µg/mL)
Escherichia coli
MDR non-MDR
Table 7 - MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates. 
 
Table 75 - MIC50 values of susceptibility for MDR and non MDR Klebsiella pneumoniae isolates.Table 76 - 
MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates. 
 
Table 77 - MIC50 values of susceptibility for MDR and non MDR Klebsiella pneumoniae isolates. 
 
 
Chapter IV.Table 78 - MIC50 values of susceptibility for MDR and non MDR Klebsiella 
pneumoniae isolates.Table 79 - MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates. 
 
Table 80 - MIC50 values of susceptibility for MDR and non MDR Klebsiella pneumoniae isolates.Table 81 - 
MIC50 values of susceptibility for MDR and non MDR Escherichia coli isolates. 
 
Table 8 - MIC50 values of susceptibility for MDR and non MDR Klebsiella pneumoniae isolates. 
 
 
Chapter IV.Table 82 - MIC50 values of susceptibility for MDR and non MDR Klebsiella 
pneumoniae isolates. 
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Table 8 - MIC50 values of susceptibility for MDR and non MDR Klebsiella pneumoniae isolates. 
 
 
Chapter IV.Table 92 - MIC50 values of susceptibility for MDR and non MDR Klebsiella 
pneumoniae isolates. 
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3. Conclusion 
 
Complicated intra-abdominal infections (cIAIs) remain an important cause of morbidity 
(Sartelli et al. 2013).  
Prompt identification the pathogens is essential for clinical management, to provide 
empiric antimicrobial therapy. For example, the detections of MDRs, by rapid microbiologic 
tests, providing a result on the same day could be used for patients with IAIs. These tests should 
be considered when patients showing high-risk factors, such as, antimicrobial therapy 
administered with seven days before operation on hospital admission. This approach is useful to 
implement infection control measures quickly, minimize cross-transmission and allow 
antimicrobial optimization. The antimicrobial optimization may lead to decreased mortality rate, 
hospitalization time and hospitalization costs (Labricciosa et al. 2018).  
The emergence of resistance among Gram-negative bacteria, especially 
Enterobacteriaceae ESBL producers, multi-drug resistant strains, and P. aeruginosa has been a 
cause for major concern. The problem of resistance left clinicians with few viable alternatives 
and its necessary the development of new drugs that show activity against resistant strains 
(Mohamed et al. 2018; Seifert et al. 2018; Shortridge et al. 2018).  
Ceft/Taz was shown efficient against Enterobacteriaceae and P. aeruginosa, including 
some microorganism ESBL producer and MDR, since was effective against almost all isolates 
(46/47). However, it is necessary to use this antimicrobial with precaution in order to prevent the 
development of resistance by microorganisms.   
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Abstract: "O (ir)resistível mundo dos antibióticos", is an activity included in the Projeto 
de Estímulo à Mobilidade de Ideias (PEMI), an educational project that is based on the 
awareness of Science and Health issues, aimed at social transformation, developed by 
Association for World Innovation in Science and Health Education (AWISHE). It was a different 
class, adapted to the objectives of the discipline "Health and Environment", that took place in the 
Agrupamento de Escolas de Oliveirinha, for 14 students at risk of dropping out of school. 
Experimental activities were carried out with the objective of consolidating the acquired 
knowledge. With this action it was possible to promote the interest, awareness and formation of 
opinions and appropriate decisions regarding the use of antibiotics. The results of the 
questionnaires, corroborate this, since the results showed that the grades obtained were positive 
in more than 70 %. 
 
Key-words: antibiotics, resistance, WHO, AWISHE, PEMI, alternative curricular course 
 
1. Introduction 
 
The discovery/production of antibiotics in the first half of the previous century and its 
subsequent introduction into the clinic was one of the greatest achievements of medicine (Van 
Hoek et al. 2011). The use of antimicrobial agents reduced morbidity and mortality in humans. 
In addition, it has allowed the treatment of hitherto incurable diseases, contributing to the 
increase of life expectancy of the human being. In the modern era of medicine, antibiotics have 
become necessary in medicine, as in organ transplants (Van Hoek et al. 2011; Khan et al. 2018). 
The development of new antimicrobial families over the years has allowed us to believe 
that we could always stay ahead of pathogens (World Health Organization 2001). 
Although the resistance is a natural and biological phenomenon, in the preceding decade, 
we saw an increase in antimicrobial resistance in pathogens. The prevalence of resistance varies 
between geographical regions and over time, but sooner or later resistance emerges to every 
antimicrobial (World Health Organization 2001; Khan et al. 2018). 
Antibiotic resistance as one of the most important public health of the 21st-century, more 
than 700,000 people die around the world due to resistant infections. In some instances, 
resistance to antimicrobial agents is seriously compromising treatment outcome (World Health 
Organization 2001; Khan et al. 2018). 
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According to World Health Organization (WHO), resistant microorganisms are strains 
able to multiply in presence of drug concentrations higher than the concentrations in humans 
receiving therapeutic doses (Van Hoek et al. 2011). 
Antimicrobial excessive use is the key driver of resistance. However, the inappropriate 
use of antimicrobial agents is, also, associated with the emergence of resistance: misuse due to 
lack of access and underuse due to lack of financial support to complete treatment courses 
(World Health Organization 2001). 
For this reason, control the spread of resistance and improving use are a priority. Several 
recommendations have been proposed by WHO for these and many of the recommendations are 
based on education. 
Although most antimicrobial use occurs in the community, the intensity of use in 
hospitals is far higher. Hospitals are therefore important in the containment of antimicrobial 
resistance. In this environment is crucial to develop approaches to improving the use of 
antimicrobials, reducing the incidence and spread of hospital-acquired infections. 
For this, it is necessary to educate healthcare workers, prescribers, dispensers and general 
community. 
In addition, all prescriber and distributor groups about the importance of proper use of 
antimicrobials, disease prevention, and infection control. From here it is important to encourage 
them to educate their patients about the use of antimicrobials and the importance of adherence to 
prescribed treatments. 
Furthermore, educate patients and the general community on the appropriate use of 
antimicrobials, on the importance of measures to prevent infection (such as immunization, vector 
control, use of bednets, etc.), on simple measures that may reduce transmission of infection in 
the household and community (such as handwashing, food hygiene, etc.), encourage appropriate 
and informed health care seeking behaviour, on suitable alternatives to antimicrobials for relief 
of symptoms and discourage patient self-initiation of treatment, except in specific circumstances. 
Education should be the basic tool for the development of individuals. Thus, the 
educational process must begin as early as possible in their lives. In order for children and young 
people to achieve levels of knowledge that enable them to make a difference in communities, 
including prevention and health care. 
To promote this education in all areas, the WHO have the responsibilities, such as, raise 
awareness of the problems posed by antimicrobial resistance, promote the sharing of information 
about and understanding of resistance, provide strategic and technical guidance on interventions 
to contain resistance, assist Member States to implement these interventions, stimulate research 
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to address the knowledge gaps and improve understanding of antimicrobial resistance and to 
encourage research and development of new antimicrobial agents. 
Some projects are already implemented in world for achieve these goals. For example, in 
1998, the WHO with many partners, development a strategy to provide, for all Member States, a 
framework of interventions to stimulate the prevention of infection, to slow the emergence of 
resistance and to reduce the spread of resistant microorganisms, in order to reduce the impact of 
resistance on health and health care costs, while improving access to existing agents and 
encouraging the development of new agents. 
The World Health Assembly (WHA) Resolution of 1998 urged Member States to 
develop measures to encourage appropriate and cost- effective use of antimicrobials. This 
requires attention in sence for prohibit the dispensing of antimicrobials without the prescription 
of a qualified health care professional, to improve practices to prevent the spread of infection and 
thereby the spread of resistant pathogens. In addition, strengthen legislation to prevent the 
manufacture, sale and distribution of counterfeit antimicrobials, the sale of antimicrobials on the 
informal market and to reduce the use of antimicrobials in food-animal production.  Countries 
were also encouraged to develop sustainable systems to detect resistant pathogens, to monitor 
volumes and patterns of use of antimicrobials and the impact of control measures. 
Since the WHA Resolution, many countries have expressed growing concern about the 
problem of antimicrobial resistance, and some have developed national action plans to address 
the problem (World Health Organization 2001). 
In Portugal, one of these examples is AWISHE (Association for World Innovation in 
Science and Health Education).  
This project has as main objectives realize training and awareness actions about Science 
and Health subjects, the development educational activities for children, youngsters and adults 
and a permanent link with educational and cultural programs. In addition, promote the 
development of national and international Collaborative Learning Communities and access to 
information, educational opportunities, training and development (AWISHE). One of the 
approaches developed by AWISHE is the PEMI (Projeto de Estímulo à Mobilidade de Ideias). 
PEMI is an educational project that aims to bring to schools a versatile, accessible, and fun yet 
rigorous scientific knowledge and has as its fundamental principle the conscientization of 
science and health through education. It is intended to rise awareness into students to the 
importance of avoiding risk behaviours, and to take actions that lead to a good quality of life, 
individual and community. 
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This project intends to fill a void of alternative resources for a group of students at risk of 
dropping out of school, with an Alternative Curricular Course. In this situation, there are students 
with no expectations of the future, with interests that are parallel to the school and, therefore, 
need training for the exercise of citizenship after compulsory schooling, making them informed 
citizens, responsible, and intervening in society. These students attend compulsory subjects, but 
with a focus on the outside world. Thus, in addition to the structural component (Portuguese and 
Mathematics) and the school offers in the vocational component (gardening, table service, event 
organization, restoration and image), the "Health and Environment" discipline is also proposed in 
the context of the sciences. 
This project is being implemented in primary and secondary schools, where scientific 
lectures and practical activities related to them are given. 
The team is composed of scientists from different areas, such as Microbiology, 
Anthropology, Medicine, Neurosciences, among others. In addition to the AWISHE team, 
researchers and physicians are involved in this project. 
 
2. Material and methods 
 
Considering all the above, one of the activities developed by PEMI was "O (ir)resistível 
mundo dos antibióticos". 
This different class took place at the school E/B 2 3 Castro Matoso belonging to the 
Agrupamento de Escolas de Oliveirinha, for a class of 14 students at risk of dropping out of 
school, with an Alternative Curricular Course. To this end, hands-on activities were carried out 
in order to consolidate the knowledge acquired, without losing scientific objectivity and 
accuracy. 
It is focused on the awareness and scientific dissemination of the great global health 
problem we face today: resistance to antibiotics. To do so, a brief approach to bacteria, different 
types of antibiotics, and how excessive and improper use has led to the development of 
resistance to antibiotics. 
One of the activities developed by "O (ir)resistível mundo dos antibióticos" intended to 
show its constitution of a bacterium. To do so recreational illustrations of a bacterial cell the 
organelle was used, the students were supposed to match nomenclature and function. 
It was also intended that students could distinguish Gram-positive and Gram-negative 
bacteria, using Gram staining. Representative coccus and bacillus schemes were used to allow 
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comparison with their microscopic form. For this, strains of Staphylococcus aureus and 
Escherichia coli, respectively, were used. 
In addition, through the use of a time-line linking different classes of antibiotics and their 
discovery, it was possible to understand the appearance of antibiotics and resistance as a natural 
and biological phenomenon. It was also raised the awareness to the problem of excessive use of 
antibiotics, which leads to the rapid spread of resistance. In the course of this, it was shown how 
the different classes of antibiotics and their mechanism of action act on the bacterium. 
At the end of the session, a questionnaire with six multiple-choice questions was applied 
to all students, testing the essential topics covered. 
 
3. Results and Discussion 
 
During the session, the students were participative and attentive, especially during hands-
on activities. In addition, we find it difficult to convey some scientific terms. However, it is here, 
in this process of communication / education, that lies the real challenge, since sometimes it is 
not easy to translate into current language this knowledge. 
The questionnaire distributed at the end of the session obtained 70% of the positive 
classifications, validating project application and student acceptance. However, there were also 
very negative outcomes: students with only one or two correct answers. Thus, the development 
of alternative methods of evaluation could show a greater receptiveness of the content addressed. 
 
4. Conclusion 
 
This class focused on the awareness and scientific dissemination of the great global 
health problem that we are facing today: resistance to antibiotics. In this work, we have been 
able to promote the interest, awareness and formation of opinions and appropriate decisions 
regarding antibiotics. 
I think this experience has been enriching for students and teachers, as it was for me. 
Students were able to enjoy a lesson with a different methodology, including hands-on activities 
to captivate their attention, with different people to teach them about other subjects. With special 
emphasis on behaviors and actions that can be apprehended and easily replicated, so that all who 
receive them become part of a community conscious and proactive 
The teachers were also able to learn a little about the subjects covered and share the 
lessons with other teams, in this case, microbiologists. 
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For me, as a speaker, this experience was very rewarding, since we were able to deliver 
knowledge and practices to the younger audience in an interactive way, favoring the connection 
between the scientific hypothesis and the world around them. For these kinds of problems, it is 
necessary to act upstream of the problem, and for this an effort has to be made to educate the 
population. This is achieved through the provision of scientifically correct information. In 
addition, this information must be presented in a simple enough way so that even the least 
literate citizen can understand what is being transmitted. 
The PEMI team intends to expand this type of activity to regular teaching groups, 
covering other levels of education. In other words, in addition to the application in non-regular 
classes, PEMI is also a complement to the regular curriculum traditionally applied, promoting a 
differentiated and attractive perspective of the different topics covered, as well as hans-on 
activities that consolidate the knowledge acquired. 
Considering the potential for growth and applicability, PEMI will continue to promote 
the inclusion of students from different contexts as well as promoters who will be part of it. The 
intervention of the PEMI is not intended to be differentiated from its capabilities, but rather 
inclusive and applicable to all types of classes. 
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ANNEX I: GRAM STAINING 
 
Early in the history of bacteriology, the detection of bacterial cells in the tissues was 
difficult, since most staining methods used coloured the bacterial cells.  
Christian Gram development a procedure able to differentiate microorganisms from 
tissue cells.   
Nowadays, the Gram reaction is a classic technique, widely used in microbiology 
laboratories and is the first step in the identification of bacterial species, given the characteristic 
behaviour of these before the Gram method. This method allows to distinguish Gram-positive 
and Gram-negative bacteria, according to the constitution of the cell wall of the bacteria. Gram-
positive bacteria have a thick layer of peptidoglycan, while Gram negative bacteria have a more 
complex cell wall and a thin layer of peptidoglycan. Gram-positive bacteria blush violet, while 
Gram negative blush red with safranin. This procedure also allows visualizing the morphology of 
bacteria and classifying them into cocci and Gram positive or negative bacilli. 
 
Gram staining procedure: 
1. Place a drop of microbial suspension on the slide and make a smear; 
2. Dry and set by moderate heat; 
3. Cover the smear with crystal violet solution and allow to stand for 1 minute; 
4. Drain the dye and wash under running water; 
5. Cover the smear with lugol solute and let it act for 1 minute, wash under running water; 
6. Discourage with alcohol-acetone for 30 seconds and rinse with water; 
7. Cover the smear with safranin for 30 seconds; 
8. Drain the dye, wash with water and allow to air dry; 
9. Observe the optical microscope with immersion objective (100x): a) Violet-stained 
bacteria are designated Gram-positive. b) Red stained bacteria are designated Gram-
negative bacteria. 
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ANNEX II:   POSTER ECCMID 2019 – “SURVEILLANCE OF 
PLASMID-MEDIATED MCR-1 GENE IN HUMAN ISOLATES, IN 
AVEIRO, PORTUGAL” 
 
Abstract:  
Background: Bacterial infections continue to be one of the leading causes of morbidity 
and mortality worldwide. Excessive and imprudent use of antibiotics led to the increase of 
resistance narrowing the therapeutic options. Colistin belongs to the family of polymyxins, with 
broad-spectrum activity against Gram-negative bacteria, including most species of the family 
Enterobacteriaceae and it is considered the last resource for MDR or XDR phenotype therapy. 
The emergence of colistin resistance has caused great concern and resistance mediated by the 
plasmid-borne mcr-1 gene has been detected worldwide in Multidrug resistant (MDR) 
Enterobacteriaceae. The aim of this study was to evaluate the presence of this gene in strains 
from patients attending the Centro Hospitalar do Baixo Vouga, E.P.E., Portugal. 
Materials/methods: All the isolates included in this study were non-duplicate and 
identified with the automated method VITEK2® (BioMèrieux, France), using the Gram-negative 
bacteria identification card, antimicrobial susceptibility testing (AST) was estimated and the 
advanced expert system (AES) suggestions were taken in consideration. The strains identified as 
susceptible to colistin were confirmed by MICRONAUT-S broth microdilution Colistin MIC test 
(Merlin Diagnostika). Polymerase chain reaction technique was used to screen for the presence 
of the colistin resistance plasmid mediated mcr-1 gene.  
Results: During the timeframe of this study (2017-2018) a total of 6189 strains were 
isolated among them nine strains exhibited non-intrinsic resistance to colistin were collected (5 
Klebsiella pneumoniae, 2 Escherichia coli, 1 Pseudomonas aeruginosa and 1 Hafnia alvei). Five 
strains were recovered inpatients and the other four were isolated from outpatient samples. 
Patients age range from 56 to 89 years-old. The mcr-1 gene was detected in one Escherichia coli 
strain. 
Conclusions: The results of this study show that the mcr-1 gene was present, as 
previously described. However, it does not explain the resistance in found in all the strains 
included in this study. Further studies will be undertaken to screen for the presence of other 
genes. Since the prevalence rate of carbapenem resistant Enterobacteriaceae (CRE) has been 
increasing in our region, we highlight the importance of a Surveillance Program to monitor the 
spread of the plasmid-mediated colistin resistance genes into MDR Gram-negative bacteria.
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ANNEX III: POSTER SCICOM PT 2019 - MOBILIDADE DE IDEIAS NO 
CAMINHO DA INCLUSÃO 
 
Abstract:  
O Projeto de Estímulo à Mobilidade de Ideias (PEMI) é um projeto educacional 
desenvolvido pela Association for World Innovation in Science and Health Education 
(AWISHE), e é impulsionado pelo princípio fundamental desta associação: a consciencialização 
para assuntos de Ciência e Saúde através da Educação. Do portfolio da AWISHE fazem parte 
outros programas de comunicação de Ciência, nomeadamente projetos internacionais de 
formação de professores e profissionais de Saúde, sempre com foco na Saúde.  
O PEMI, a ser implementado em escolas do ensino básico e secundário, dinamiza 
palestras de carácter científico, como veículo de informação entre a comunidade científica e as 
escolas, que incluem atividades práticas hands-on para consolidar os temas abordados em cada 
sessão. 
Dentro das diferentes áreas que este projeto leva às escolas, são abordados temas de 
interesse aos jovens em idade escolar, com especial ênfase em comportamentos e ações que 
podem ser apreendidos e facilmente replicados, para que todos quantos os recebam passem a 
fazer parte de uma comunidade consciente e pró-ativa.  
Até à data, a equipa do PEMI é constituída por investigadores, médicos e enfermeiros, 
com a missão de levar às escolas conhecimento científico rigoroso e versátil, bem como 
acessível e divertido. A equipa está disponível para complementar a matéria do professor com 
momentos de partilha de conhecimentos e boas práticas, de uma forma interativa, favorecendo a 
ligação entre o manual escolar, a hipótese científica e o mundo que nos rodeia. 
Na génese deste projeto esteve a necessidade de preencher um vazio de recursos 
alternativos para uma turma de alunos em risco de abandono escolar, com um Percurso 
Curricular Alternativo. Nesta situação, estão alunos sem expectativas de futuro, com interesses 
paralelos à escola, e que necessitam de formação para o exercício da cidadania após a 
escolaridade obrigatória, tornando-os cidadãos informados, responsáveis, e   intervenientes na 
sociedade. No entanto, a intervenção do PEMI não pretende ser diferenciadora das suas 
capacidades, mas antes inclusiva e aplicável a todo o tipo de turmas. Os temas oferecidos vão de 
encontro a grande parte do currículo escolar, tanto do ensino regular como dos currículos 
alternativos oferecidos pelas escolas. 
 Annex III: Poster SciCom Pt 2019 - Mobilidade de ideias no caminho da inclusão 
92 
 
Numa primeira fase, o PEMI foi implementado, ao longo do 2º período do ano letivo 
2018/2019, no Agrupamento de Escolas de Oliveirinha, numa turma de Percurso Curricular 
Alternativo, com 25 alunos. A estes alunos é pedido que frequentem disciplinas de carácter 
obrigatório, mas numa vertente mais social e menos teórica. No contexto das Ciências, uma das 
disciplinas propostas é a disciplina “Saúde e Ambiente”, onde se integrou o PEMI, 
sensibilizando os alunos para a importância de evitar comportamentos de risco, e assumir ações 
que levem a uma boa qualidade de vida, individual e comunitária. No final de cada sessão, foi 
aplicado a todos os alunos um questionário de escolha múltipla, testando os tópicos essenciais 
abordados. Até à data, as classificações foram positivas em mais de 50% dos alunos envolvidos, 
validando aplicação do projeto e aceitação por parte dos alunos. 
Para além da aplicação em turmas de ensino não regular como esta, o PEMI constitui 
também um complemento ao currículo regular. Considerando o potencial de crescimento e 
aplicabilidade, o PEMI vai continuar a promover a inclusão, tanto de alunos de diferentes 
contextos, como de promotores que dele vierem a fazer parte.   
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ANNEX IV: POSTER SCICOM PT 2019 – “O (IR)RESISTÍVEL 
MUNDO DOS ANTIBIÓTICOS” 
  
This poster was classified as the “2nd best poster” of the SciCom2019 congress, held in 
Aveiro. 
 
Abstract: 
“O (ir)resistível mundo dos antibióticos”, é uma atividade enquadrada no Projeto de 
Estímulo à Mobilidade de Ideias (Projeto da Escola da Mãe da Inês, PEMI), um projeto 
educacional que tem por base a consciencialização de assuntos de Ciência e Saúde, visando a 
transformação social, desenvolvido pela Association for World Innovation in Science and Health 
Education (AWISHE). 
Esta aula diferente, adaptada aos objetivos da disciplina “Saúde e Ambiente”, ocorreu no 
Agrupamento de Escolas de Oliveirinha, para uma turma de cerca de 20 alunos em risco de 
abandono escolar, com um Percurso Curricular Alternativo. 
Incidiu na consciencialização e divulgação científica do grande problema de saúde global 
com o qual nos deparamos hoje em dia: a resistência aos antibióticos. Para tal, iniciou-se uma 
breve abordagem às bactérias, aos diferentes tipos de antibióticos e de que forma o seu uso 
excessivo levou ao desenvolvimento de resistência aos mesmos. 
O discurso foi ajustado às especificidades do público-alvo, dinamizando uma aula de 
carácter científico, recorrendo a atividades lúdicas, motivando e captando a audiência, por forma 
a consolidar o conhecimento adquirido foi consolidado, sem nunca perder a objetividade e rigor 
científicos. 
Das atividades experimentais e demonstrações realizadas salientamos a visualização, ao 
microscópio ótico, das diferenças pela coloração de Gram, e a realização de uma linha temporal 
para a compreensão da ligação entre o uso exagerado de antibióticos e a sua resistência, entre 
outras. 
Espera-se com este tipo de ação conseguir promover o interesse, sensibilização e 
formação de opiniões e decisões apropriadas, relativamente ao uso de antibióticos. 
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ANNEX V: ABSTRACT OF ICID 2020– EPIDEMIOLOGY OF 
CARBAPENEMASES-PRODUCING BACTERIA IN CENTRO 
HOSPITALAR BAIXO VOUGA 
 
Abstract: 
Infectious diseases caused by bacteria are one of the major health problems. The 
emergence of carbapenemases such as KPC, which have a high capacity of dissemination, 
increased this problem thus being motive of concern. The aim of this study was to evaluate the 
presence of KPC gene and their distribution in strains collected in Centro Hospitalar do Baixo 
Vouga, E.P.E., Portugal. 
All isolates included in this study are non-duplicate and were identified using Gram-
negative bacteria identification card of the automated system VITEK2® (BioMèrieux, France), 
antimicrobial susceptibility testing (AST) was estimated and advanced expert system (AES) 
rules were taken in consideration. CarbaNP (BioMèrieux, France) test was used, according to 
manufacture’s instructions, to confirm the presence of a carbapenemase. Strains with a positive 
result were further studied by PCR, to confirm the presence of KPC gene and divided into 
different clusters. In addition, a PCR scheme was designed to detect the distribution of blaKPC-
harboring IncFIA (pBK30661-like and pBK30683-like) plasmids when they present the KPC 
gene. 
During the timeframe of this study (2017-2018) a total of 6189 strains were isolated 
among them 61 Enterobacteriaceae and 3 Pseudomonas aeruginosa exhibited resistance to the 
carbapenems. Among all the isolates Klebsiella pneumoniae was the most relevant species since 
52 strains were identified. The remain isolates were: five Enterobacter cloacae, one Escherichia 
coli, one Citrobacter freundii and one Enterobacter aerogenes. The PCR was positive for the 
presence of the KPC gene in 50 of 52 strains, which were all Klebsiella pneumoniae. The strains 
of Klebsiella pneumoniae are divided into 26 clusters, Enterobacter cloacae into 4 different 
clusters and Pseudomonas aeruginosa into 2 clusters by BOX-PCR. KPC-harboring IncFIA 
plasmids were found in 27 of 52 K. pneumoniae isolates. 
The results of this study show that in our region, as expected, the KPC gene was 
prevalent in the Klebsiella pneumoniae and the majority was transferred in IncFIA plasmid. 
Nonetheless the percentage of carbapenems resistant Enterobacteriaceae being low (1%), it’s 
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extremely important to apply earlier diagnostic techniques, such as molecular techniques, that 
will help to contain the spread more rapidly. 
 
